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Abstract
Computational drug design and discovery methods have traditionally put much
emphasis on the identification of novel active compounds and the optimization
of their potency. For chemical genetics and genomics applications, an impor-
tant task is the identification of small molecules that are selective against target
families, subfamilies, or individual targets and can be used as molecular probes
for specific functions. In order to develop or tune computational methods for
such applications, there is a need for molecular benchmark systems that focus
on compound selectivity, rather than qualitative biological activity or potency.
Two selectivity-oriented test systems have been designed that consist
of several compound selectivity sets for individual targets belonging to distinct
protein families. Compound selectivity sets were characterized by structural di-
versity, chemical scaffold, and selectivity range analysis. These compound sys-
tems were especially designed for selectivity studies. Thus far, computational
methods have had only little impact on the search for selective compounds.
This is in part due to the fact that selectivity is more difficult to study than
activity because selectivity analysis requires the evaluation of compounds bind-
ing to multiple targets.
Here, we have investigated the ability of state-of-the-art 2D molecular
fingerprints and a mapping algorithm to detect compounds having different
selectivity profiles. The results of systematic similarity search calculations re-
vealed that these computational methods are capable of identifying compounds
having different selectivity against closely related target proteins, although they
were originally not developed for such applications.
Finally, we have successfully applied these methodologies to introduce in
silico selectivity searching for the identification of cathepsin K inhibitors. On
the basis of computational analysis, 16 candidate molecules taken from 3.7 mil-
lion database compounds were tested and two inhibitors identified that showed
a clear selective tendency for cathepsin K over cathepsin S and L. One of these
inhibitors represents a previously unobserved chemotype.
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Chapter 1
Introduction
The ’central dogma’ of molecular biology proposed in the 1950s explains the in-
formation flow through macromolecules from DNA to RNA to proteins (Crick,
1958, 1970). Today, small molecules (usually ≤500 Da) - like metabolites,
transmitters, hormons or xenobiotics - are sometimes seen as a ’missing link’ in
the ’central dogma’. They can play key roles in cellular processes like signaling
and are critical for the understanding of biological systems, their regulation,
and also for treatment of diseases (Schreiber, 2005). Many biological processes
can be reduced to chemical reactions and depend on the structure and interac-
tions of the participating molecules. In order to investigate the effects of small
molecules in biological systems, new interdisciplinary and fast growing research
fields including chemical biology, chemogenomics, and chemical genetics have
evolved at interfaces between synthetic and medicinal chemistry, biology, genet-
ics, pharmacology, chemo- and bioinformatics, structural biology and biological
screening (Jacoby, 2006; Spring, 2004). These research fields generally focus on
the use of small molecules to inhibit or activate cellular targets and modulate
biological functions (Tan, 2005; Stockwell, 2004). They are closely related to
each other and their boundaries are fluid.
The main task of chemical biology is to investigate biological systems
and processes using small chemical compounds. Chemical genetics is the study
of small molecule intervention instead of classical genetic manipulations and
concentrates on the identification of small molecules that induce or revert spe-
cific biological phenotypes (Jacoby, 2006; Spring, 2004). As in classical genetics
the discovery of connections between biological phenotypes and protein-ligand
interactions can be elucidated in two ways: A ’forward’ approach is the appli-
cation of small molecules to functional assays with multiple target proteins to
identify a specific or interesting phenotype and the corresponding ligand-target
complex. In a ’reverse’ approach, small molecules interfering in a desired way
with a protein of interest are utilized as probes to dissect biological functions.
The chemogenomics field has the ambitious goal to ultimately relate all
possible drugs to all possible drug targets (Caron et al., 2008), which requires
1
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the systematic evaluation of interactions between drugs and drug candidates
with biological targets. Therefore, these efforts are also related to target family
approaches, where ligands of family members are systematically characterized
based on their activities against all investigated family members.
Research in these fields produces large amounts of data, ranging from
genomic information over chemical libraries to ligand-target interactions. The
development and evaluation of computational tools to help address key prob-
lems in chemical biology is of significant relevance for further advancing this
field. Such computational approaches include, for example, small molecule
similarity methods, analyses of structure-activity or -selectivity relationships,
or the construction of target similarity and ligand-target interaction networks.
Computational Methods for Chemical Biology
Computational methods applied in chemical biology can be classified on the ba-
sis of two major goals: the derivation of knowledge from large-scale analysis of
available ligand and target data and, furthermore, the integration of biological
screening efforts with predictive computational methods (Bajorath, 2008b).
For computational analysis, small molecules must often be mapped to
chemical reference spaces, in which further calculations, analysis, or design are
carried out. Chemical space is an N -dimensional space defined by computa-
tional descriptors of molecular structure and physical or chemical properties. A
general assumption, often referred to as the similarity property principle (SPP),
states that similar molecules have similar biological effects and map to similar
regions in chemical space (Johnson & Maggiora, 1990).
Protein target similarity can be assessed by the ’classical’ analysis of
sequence homology or by building target networks. In target space relation-
ships between target proteins are organized based on cross-activity of ligands.
Promiscuous ligands link several target proteins. The more ligands two target
proteins share, the closer they are located in target space. Another approach
is to calculate the chemical similarity of a set of ligands binding to one target
with a ligand set binding to another one. Based on the calculated similarity
of their ligand sets, the targets are connected. A pioneering example has been
described by Frye who identified targets that showed similar patterns in the
structure-activity data of their ligands from high-throughput screening data
and therefore considered them as ’structure-activity relationship (SAR) homol-
ogous’ (Frye, 1999). Such approaches have revealed, for example, that many
more interactions between individual drugs and targets occur than previously
thought and that many targets are promiscuous in nature (Paolini et al., 2006;
Yildirim et al., 2007), which has recently been referred to as polypharmacology.
For the assessment of global pharmacology space, which describes the
regions of chemical space populated with therapeutically relevant ligand-target
3interactions, compound profiling represents a first step (Bajorath, 2008a). It
describes the design of ligand-target interaction networks where all activity
data for ligands is used to link them with target proteins in order to reveal
the degree of ligand or target promiscuity. In this context, molecular similar-
ity of ligands can also be established based on their ’activity spectra’. So far,
most of the computational compound profiling approaches concentrate only on
individual protein families such as kinases or nuclear receptors (Fabian et al.,
2005; Mestres et al., 2006) and even current global mapping of ligand-target
space attempted, for example, by Paolini et al. still covers only subsection of
theoretically available space.
Ligand space can be used to calculate the chemical similarity of all lig-
ands under investigation and group similar molecules together. Annotating
such ’ligand clusters’ with their biological targets makes it possible to predict
’activity spectra’ of untested molecules towards target proteins by calculating
their similarity to the known ligands and place them in the most similar ’cluster’
(Bajorath, 2008a).
Compound Selectivity
Recently, another drug similarity network was presented that was based on side
effect similarity drawn from known drug side effects (Campillos et al., 2001).
Side effects often result from drugs that are highly potent against isolated tar-
gets in vitro but bind to additional targets in vivo (Dobson, 2004). Selective
binding means that a ligand discriminates between alternative targets by pref-
erentially binding to only one with high potency. However, compound promis-
cuity can often be observed in target families where family members show a
high degree of binding site conservation (Jacoby, 2006).
Because biological functions of closely related proteins might vary, the
elucidation of protein function in biological systems is heavily dependent on the
availability of target-selective ligands. Otherwise, the use of small molecules to
interfere with biological processes will not result in a target-specific cellular re-
sponse (Bajorath, 2008b). Therefore, the discovery and confirmation of truly
selective ligands is also critical for the analysis of biological systems in chemical
biology as well as their progression into viable leads or drugs in drug develop-
ment.
Although much progress has been made in the design of computational
tools for chemical biology, the development of methods for compound selectivity
analysis is still in its infancy. The difficulty in obtaining relevant test systems
such as collections of ligands showing target-selectivity within protein families
continues to be a limiting factor for the development of such methods. The
availability of compound systems that comprise compound binding data across
a range of protein targets is indeed required for a direct evaluation of compound
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selectivity and the analysis of structure-selectivity relationships (SSRs). Such
compound collections also provide a solid basis for the use of computational
methods to detect and predict target-selective molecules, the identification of
which has thus far mostly relied on experimental screening and subsequent
chemical optimization efforts.
Goals
This thesis project has aimed to develop and validate computational approaches
for the analysis of compound selectivity, which have high potential for appli-
cation in chemical biology. In order to provide a basis for selectivity analysis,
different compound selectivity systems were designed and assembled. The sys-
tems were utilized to evaluate different computational methods for their ability
to distinguish between target-selective, non-selective, and inactive compounds.
On the basis of these investigations, selectivity search protocols were established
and applied to mine large compound databases for target-selective inhibitors. In
a proof-of-concept study, small molecules with a clear target-selective tendency
for cathepsin K were experimentally confirmed including a novel inhibitory
chemotype.
5Thesis Outline
The development and invention of selectivity searching is the objective of this
thesis. Starting point was the assembly of viable and relevant selectivity com-
pound test systems from scientific literature. Based on these set systems the
potential of computational methodologies in simulated virtual screening ap-
proaches to identify target-selective ligands was tested and applied in a practi-
cal virtual screening.
Chapter 2 concentrates on the analysis and design of two compound
benchmark systems, which contain compound sets with different selectivity pro-
files against targets of closely related proteins. The compound systems include
selective vs. inverse-selective and selective vs. non-selective molecule sets for
two biological targets in different combinations of proteins from several protein
families.
In Chapter 3, conventional similarity search methods are examined by
using the two benchmark systems for their potential to identify target-selective
ligands. A scenario referred to as selectivity searching instead of similarity
searching.
Chapter 4 presents for the first time ligand-based virtual screenings
which have been utilized to intentionally identify compounds having at least a
target-selective tendency. In this experimental application two compounds with
the same target selective tendency as the reference compounds were biologically
tested and confirmed.
Chapter 2
Design of Selectivity Sets
This chapter reports the design of two selectivity benchmark systems that con-
sist of a variety of compound subsets showing different selectivity patterns that
make it possible to evaluate differences in ligand selectivity between individual
members of different target families. The first benchmark system presented
here concentrates exclusively on the selectivity of a ligand against two targets
belonging to the same protein family (Stumpfe et al., 2007), whereas the second
benchmark system also contains non-selective molecules and potency ranges of
ligands (Stumpfe et al., 2008). As a basis for compound selectivity we defined
a selectivity criterion as a fixed potency ratio of a ligand over two targets.
The detailed compound set composition is reported followed by the analysis of
compound diversity and structure-selectivity relationships (SSRs).
2.1 Selectivity Criterion
Compound selectivity was defined on the basis of differences in potency values of
a ligand for two proteins. The potency ratio of a ligand over two targets, in the
following also referred to as selectivity ratio (SR), is calculated from either itsKi
or IC50 values. Ki is the dissociation constant of an enzyme-inhibitor complex,
or the reciprocal of the binding affinity of a ligand to a target. The IC50 value
represents the concentration of an inhibitor that is required for 50% inhibition of
an enzymatic reaction at a specific substrate concentration. Altough the IC50
value is dependent on the substrate concentration in the assay, both values
can be related to each other by using the Cheng-Prusoff equotation (Cheng &
Prusoff, 1973). In our analyses we used both values because additional data
needed for a conversion was often not available.
In our benchmark systems, a compound was considered selective for a
given target if its Ki or IC50 value was at least 50-fold lower for one target than
for other targets within the same family. This is equivalent to a SR of 50. The
SR of a ligand for two targets (T1,T2) is defined as follows:
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Figure 2.1: The selectivity criterion
The potency ratio of a ligand for two targets is used as selectivity criterion (SR). A ligand
with a SR ≥ 50 for a given target is considered selective. In this example the inhibitor is
selective for cathespin (cat) S. The binding affinity for cat S compared to cat K (catS/catK)
is 50-fold higher, i. e. the potency value is 50-fold lower for cat S.
T1
T2
≡ SR(ligand,T1,T2) = 1 :
Ki(ligand,T1)
Ki(ligand,T2)
(2.1)
The calculation of the SR for a selective ligand of cathepsin (cat) S compared
to cat K is schematically shown in Figure 2.1.
By contrast, a compound was classified as active but non-selective for
two targets if the difference of its potency values for two targets was less than
10-fold (SR ≤ 10 for both targets). Compounds with SR greater than 10 and
smaller than 50 were not considered in our analysis.
2.2 Selectivity Sets
2.2.1 Target Survey
Initially, we surveyed a number of different target families for the availability
of significant numbers of compounds with experimentally confirmed differential
potency levels against individual targets. This survey largely determined which
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target families, subfamilies, and individual proteins were ultimately chosen and
corresponding ligands assembled. In the initial benchmark system, described in
Section 2.2.2, GPCR families, which are the most frequently occuring drug tar-
gets (Tyndall & Sandilya, 2005; Overington et al., 2006), and protease families
were selected. GPCR ligands studied here generally share a canonical molecular
organization where arylpiperazine or piperidine moieties are connected through
alkyl or alkenyl spacers to heteroaromatic systems. Variations of these struc-
tural motifs are responsible for differences in the selectivity of a ligand. In
contrast to GPCR ligands, for the most proteases studied here, a wealth of
X-ray structural information is available including complexes with selective lig-
ands (Czapinska & Otlewski, 1999; Turk & Guncar, 2003). Thus, corresponding
selectivity sets can also be evaluated in light of structural data taking known
binding modes into account, which makes it possible to apply structure-based
methods for selectivity analysis. This was another reason for focussing on pro-
tease targets. The selectivity sets were designed to include rather different
types of compounds directed against targets, for which much relevant infor-
mation was available, either at the ligand (GPCRs) or target structure level
(proteases). In the second benchmark system, described in Section 2.2.3, we
focused on enzymes as target proteins and enlarged the spectrum of protease
families and added two carbonic anhydrases as targets.
For the design of the selectivity sets, compounds were taken from the
Molecular Drug Data Report (MDDR)1, the BindingDB database (Liu et al.,
2007; Chen et al., 2002a, 2002b, 2001), original literature, and patent sources.
For each compound, it was confirmed in the original references that it was as-
sayed against different members of our selected targets, and only competitive
and reversible inhibitors (enzymes) or antagonists or partial agonists (GPCRs)
were included. Therefore, the selectivity sets were hand-selected and assembled
on a compound-by-compound basis, which ensured high quality of the data.
2.2.2 Selective and Inverse-Selective Ligands
The initial benchmark system includes compound sets selective against 13 tar-
gets belonging to three subfamilies of biogenic amine GPCRs (the alpha1 adren-
ergic receptor, 5HT1a serotonin receptor, and dopamine receptor subtypes D1-
D4), two subfamilies of papain-like thiol proteases (cathepsin B versus L, S, and
K), and trypsin-like subfamily of the serine proteases (thrombin, trypsin, factor
Xa). A detailed description of family, subfamily, and selected target relation-
ships is shown in Figure 2.2 (Jacoby et al., 2006; Guay et al., 2000; a¨gler, a¨gler;
Screen & Leger, 2000; Volanakis & Narayana, 1996; Rawlings et al., 2008).
For GPCR and cathepsin compound sets taken from database or litera-
1Software, fingerprint methods, and databases mentioned throughout this text are listed
and briefly described in Appendix A.
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Figure 2.2: The initial selectivity benchmark system
Family relationships for the targets from benchmark system 1 are shown.
ture sources, a compound was considered selective for a given target if its SR
was ≥ 50 compared to another target within the same subfamily. For the serine
protease data sets, it was possible to select sufficiently large numbers of com-
pounds that had at least a 100-fold lower Ki or IC50 value (SR ≥ 100) against
an individual target than the other targets of the same subfamily, representing
a more stringent selectivity criterion.
For the chosen thiol protease family of papain-like proteases (C1)
(Rawlings et al., 2008; McGrath, 1999; Rawlings et al., 2008), we could com-
plement compound selectivity sets collected from the scientific literature and
patent sources with data from high-throughput screening (HTS) assays to fur-
ther increase the structural diversity of compounds having different selectivity.
Cathepsin inhibitors taken from HTS data sets had to display exclusive binding
to one of three cathepsins at concentrations of up to 50 µmol/l. Cathepsin HTS
data set were obtained by merging the results of three screens for inhibitors of
cathepsins B, L and S, respectively, using largely overlapping compound source
databases. These assays were carried out at the Penn Center for Molecular
Discovery (PCMD) at the University of Pennsylvania and are publicly available
through PubChem. The intersection of these three different assays consists of
55,134 compounds including 79 hits with confirmed IC50 against only one of
2.2 Selectivity Sets 11
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Figure 2.3: Compound selectivity sets
Shown are diagrams representing all selectivity sets in our first benchmark system; A. biogenic
amine GPCR antagonists, B. cathepsin inhibitors, C. trypsin-like protease inhibitors. Every
arrow represents a selectivity set and its direction defines the selectivity. The number of
compounds in each set is also reported. For example, in A (top left), 13 compounds are
selective for D1 over D4, 20 for D4 over D1 (opposite direction), and 31 for D1 over D2.
the targets.
The 55,055 inactive compounds were used during computational selec-
tivity searching as a confirmed inactive background database for the targets of
the papain-like family (cathepsins).
The benchmark system consists of 26 selectivity sets against the 13 tar-
gets containing a total of 559 selective unique compounds as summarized in Ta-
ble 2.1. Thus, the selectivity sets provide a benchmark system of considerable
size. The selectivity sets are pair-wise organized representing a bi-directional
selectivity for two targets. Thus, one set contains selective ligands for the first
target and the other set selective molecules for the second target (’inverse-
selectives’). The number of compounds per set ranges from nine to 64, with
the majority of sets containing between 20 and 30 compounds. All selectivity
sets included in our benchmark system and their composition are schematically
presented in Figure 2.3. The compound numbers were largely determined by
our stringent selection and quality control criteria, as described above. This
also explains why it was not possible to generate selectivity sets for all cho-
sen targets. Furthermore, it is important to note that the number of selective
compounds per target generally differs for target pairs, dependent on the ’di-
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Table 2.1: Selectivity sets
Selectivity set Selectives Potency Selectivity
[pKi or pIC50] [Ki or IC50 ratio]
D1/D2 31 7.9 - 10.1 59 - 10,084
D2/D1 26 5.8 - 10.3 67 - 18,310
D1/D4 13 7.9 - 10.2 65 - 4,761
D4/D1 20 7.4 - 9.6 190 - 30,769
D2/D4 9 7.6 - 8.6 50 - 834
D4/D2 64 7.4 - 9.3 59 - 17,600
D3/D4 12 7.4 - 9.6 51 - 1,609
D4/D3 33 6.9 - 9.6 52 - 15,000
D2/5HT1a 11 7.7 - 9.7 50 - 1,621
5HT1a/D2 24 8.0 - 10.7 58 - 10,000
Alpha1/5HT1a 27 7.0 - 9.5 59 - 20,000
5HT1a/Alpha1 46 8.1 - 10.7 55 - 10,000
Cat B/L 23 4.4 - 6.6 specific HTS set
Cat L/B 33 4.4 - 6.9 specific HTS set
Cat B/S 23 4.4 - 6.6 specific HTS set
Cat S/B 23 4.5 - 6.1 specific HTS set
Cat L/S 33 4.4 - 6.9 specific HTS set
Cat S/L 23 4.5 - 6.1 specific HTS set
Cat K/S 25 6.4 - 11.3 65 - 119,298
Cat S/K 20 5.5 - 7.8 50 - 1,000
Thro/FaXa 35 6.0 - 9.2 100 - 490,000
FaXa/Thro 20 7.1 - 10.0 104 - 2,000,000
Tryp/FaXa 52 6.1 - 9.2 100 - 100,000
FaXa/Tryp 49 7.2 - 11.0 100 - 400,000
Tryp/Thro 25 6.0 - 9.0 100 - 11,428
Thro/Tryp 48 5.8 - 11.6 103 - 122,059
Compounds in each set are selective for one target over another family member. For example,
the designation D1/D2 means that the compounds in this set are selective for dopaminergic
receptor subtype D1 over D2.
rectionality’. An extreme example is provided by D4 and D2: For D4, 64
compounds were found to be selective over D2 but only nine compounds could
be confirmed as selective for D2 over D4 (Figure 2.3.A). In the case of throm-
bin, 52 inhibitors were selective for thrombin over factor Xa, but only 35 for
thrombin over trypsin (Figure 2.3.C). For all selected compounds, exact source
information is provided in Appendix B.1.1.
The selectivity ranges within these sets typically cover approximately
three orders of magnitude ranging, for example, from 67 - 18,310 (D2/D1) (see
Table 2.1). Even for the more stringent selection of serine protease ligands (SR
≥ 100), the sets cover selectivity ranges of three to four orders of magnitude
(e. g. 104 - 2,000,000 for factor Xa over thrombin).
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Figure 2.4: Classification of selective and non-selective compounds
The example shows compounds active against cathepsin K and S. Potency values of com-
pounds for cat S are plotted against the corresponding values for cat K in the pKi and pIC50
scale. Diagonals delineate the 10-fold (inner diagonals) and 50-fold (outer) potency intervals.
Compounds selective for cat S and K are colored blue and green, respectively, and non-
selective compounds with less than 10-fold difference in potency are shown in red. Dashed
lines delineate a potential range of potency for compounds in one selectivity set (here pKi or
pIC50 7-8 for S/K).
2.2.3 Selective and Non-Selective Ligands
The design of the selectivity sets from the second benchmark system differs
from those decribed in Section 2.2.2. Here, the selectivity sets consist of target-
selective molecules and, in addition, compounds that are comparably active
against related targets and thus non-selective. In consequence, every selectivity
set consists of two subsets, one subset with selective molecules (SR ≥ 50) for
one target over another closely related target and a second subset with non-
selective compounds for both targets (SR ≤ 10 for both). Figure 2.4 illustrates
the classification of selective and non-selective active compounds for cathepsin
K and S.
On the basis of the target survey, here, we focused on three papain-like
thiol proteases (cathepsin L, K, and S), two chymotrypsin-like serine proteases
(thrombin and trypsin), three matrix metallo proteases (MMP 2, 8, and 9),
and two carbonic anhydrases (CA IV and IX) as illustrated in Figure 2.5.
Non-selective compounds were also active against cathespin B, matrix metallo
protease 1 and carbonic anhydrase I, respectively, depending on the set (see
Table 2.2).
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Figure 2.5: The second benchmark system
Family relationships for the targets from benchmark system 2.
Inclusion of Potency
Furthermore, in the second benchmark system, selective and non-selective com-
pounds are classified according to different potency levels. Every selectivity set
contains only ligands that bind the target in a defined potency range. There-
fore, the Ki and IC50 values were converted into pKi and pIC50 values (-log Ki
or -log IC50), respectively (Figure 2.4). Molecules with potency values between
one order of magnitude of the pKi or pIC50 scale, i. e. values in the range of pKi
or pIC50 6-7, or 7-8, or 8-9, were assembled in one selectivity set (see Figure
2.4 and Table 2.2). These potency levels range from 1 µM (pKi or pIC50 6) to
1 nM (pKi or pIC50 9). This design of selectivity sets ensures that structural
variations between subsets are directly related to selectivity and are not the
result of compounds having very different potency (e. g. hits versus optimized
leads). Also none of the sets contains weakly potent and highly potent com-
pounds that are selective for a given target. Molecules with a potency value
above 10 µM were considered inactive.
For these 11 targets a total of 432 different unique molecules were orga-
nized into 18 selectivity sets, each including a subset of selective and a subset of
non-selective molecules, as described in Table 2.2. The number of compounds
per set ranges from 22 to 53 compounds including 10 to 31 selective and 10 to
35 non-selective compounds. Exact source information including original refer-
ences is provided in Appendix B.2.1.
As already mentioned for the first benchmark system, the intra-set se-
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Table 2.2: Second benchmark system
Data sets Actives Selectives Non Potency Selectivity
- selectives [pKi or pIC50] [Ki or IC50 ratio]
CA IV/I 30 10 20 6-7 0.9 - 618
CA IV/I 53 20 33 7-8 0.2 - 2308
CA IX/I 25 14 11 8-9 0.4 - 1441
MMP 2/1 33 19 14 8-9 0.2 - 2538
MMP 8/1 28 12 16 8-9 3.5 - 4811
MMP 9/1 40 24 16 8-9 2.2 - 5773
Cat K/B 22 12 10 6-7 0.2 - 2000
Cat S/B 23 12 11 6-7 0.2 - 860
Cat K/S 36 20 16 7-8 0.1 - 7857
Cat K/L 39 24 15 7-8 0.1 - 10714
Cat S/K 46 24 22 7-8 0.1 - 26316
Cat S/L 46 19 27 7-8 0.1 - 7667
Cat K/S 46 25 21 8-9 0.1 - 12641
Cat K/L 41 31 10 8-9 0.1 - 32173
Cat S/K 25 15 10 8-9 0.1 - 19697
Cat S/L 27 14 13 8-9 0.2 - 5556
Try/Thr 48 13 35 6-7 0.1 - 500
Try/Thr 35 25 10 7-8 0.1 - 11429
Compounds in each set are either selective for one target over another family member or
non-selective for these targets. ’Actives’ gives the total number of compounds per set. For
example, the designation ’CA IV/I’ means that the selective subset within this set consists
of compounds that are selective for carbonic anhydrase IV over carbonic anhydrase I, while
compounds of the non-selective subset have comparable activity against both targets. For
example, for set ’CA IV/I’, ’Potency’ reports the potency range of all compounds against
carbonic anhydrase IV and ’Selectivity’ the observed selectivity ranges that result from com-
parable or lower potency against carbonic anhydrase I.
lectivity distribution in these sets is heterogeneous and covers up to five orders
of magnitude, e. g. 0.1 - 10714 for the set Cat K/L 7-8 (Table 2.2).
2.3 Compound Diversity
2.3.1 MACCS Tc Similarity
The intra- and inter-set structural diversity of selective vs. inverse-selective
and selective vs. non-selective compounds was evaluated by sytematic pair-wise
calculation of the Tanimoto coefficient (Willett, 2005) using the MACCS
structural key fingerprint. MACCS is a two-dimensional (2D) fingerprint that
consists of 166 bits coding for 166 structural fragments which presence or
absence in a molecule is detected. Therefore, this fingerprint was selected
16 Chapter 2. Design of Selectivity Sets
0 1  
Selectives Non-selectives Selectives Non-selectives Selectives Non-selectives
Selectives Inverse-selectives Selectives Inverse-selectives Selectives Inverse-selectives
High diversity Heterogeneity High similarity
A
B
Figure 2.6: MACCS Tc matrices
Similarity values are reported for systematic pairwise compound comparisons. MACCS Tc
values are color-coded according to the following scheme: light green 0 - 0.2, dark green 0.2
- 0.4, grey 0.4 - 0.6, dark red 0.6 - 0.8, light red 0.8 - 1. For different selectivity sets, (A)
selective and inverse-selective and (B) selective and non-selective compounds are compared.
In each matrix, pairwise comparisons of compound subsets are divided by black bars. From
the left to the right, comparisons are reported for (A) Tryp/Thro, FaXa/Tryp, and D3/D4
and for (B), Cat K/B 6-7, Cat K/L 7-8, and CA IX/I 8-9.
to access compound diversity by emphazising structural resemblance of the
molecules. The Tanimoto coefficient (Tc) is a metric for compound similarity
and the values range from 0 (no similarity) to 1 (high similarity or equal
molecule). A more detailed description follows in Section 3.2.1 with Equation
3.1. Compound diversity and similarity are illustrated in matrices in which
increasing MACCS Tc values are colour-coded from light green (no or low
similarity) over grey to light red (high similarity or identical molecules). Figure
2.6 shows representative compound sets from the first (A) and the second (B)
benchmark system and reveals that the compound diversity distribution within
selectivity sets differs substantially. MACCS Tc matrices were calculated using
Matrix2png (Pavlidis & Nobel, 2003).
For the initial selectivity sets, one can observe that even sets belonging
to the same target subfamily are related to each other by significantly different
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degrees of diversity. As expected, GPCR ligands are in general more similar
to each other (Figure 2.6.A left) than protease inhibitors (right and center).
However, although GPCR sets are mostly -but not always- structurally
homogeneous, comparison of selectivity sets for target pairs produces rather
different diversity patterns and equivalent observations can be made for the
protease inhibitor sets that are characterized by higher intra-set diversity.
However, there are exceptions; for example, HTS hits selective for cathepsin
S and both thrombin and trypsin inhibitors selective over factor Xa have
significant intra-set similarity. By contrast, thrombin inhibitors selective
over trypsin are structurally heterogeneous (MACCS Tc matrices for all
compounds sets are provided in Appendix B.1.2). The significantly different
diversity patterns for selectivity sets demonstrate that there is no obvious
correlation between structural similarity or diversity and compound selectivity.
Structurally similar, but also structurally diverse compounds are found to
be target-selective and compounds having inverse-selectivity are also often
related by different degrees of structural diversity. A more detailed analysis of
structure-selectivity relationships is presented in Section 2.4.
Equivalent observations concerning structural diversity are made for
the selectivity sets from benchmark system 2. These sets represent again a
wide spectrum of structural diversity, ranging from structurally homogeneous
to diverse compound collections (MACCS Tc matrices for all compounds
sets are provided in Appendix B.2.2). Figure 2.6.B shows a comparison of
representative selective and non-selective compounds in different selectivity
sets and illustrates varying degrees of intra-set structural diversity. For
selectivity studies, the inclusion of structurally homogenous compound sets
is highly desired (different from conventional database searching for active
compounds). Structurally homogeneous selectivity sets present particularly
challenging test cases for similarity searching because they contain very similar
compounds that are selective or non-selective (and thus difficult to distinguish).
2.3.2 Scaffold Distribution
In order to analyze core structure distributions within selectivity sets, com-
pounds were reduced to chemical scaffolds by deleting all non-ring substituents
except linkers between ring systems. Chemical scaffolds were further reduced
to carbon skeletons by substituting all hetero atoms with carbon atoms and
converting all bond orders to single bonds. Table 2.3 gives an overview over the
number of molecules in each set and the number of different carbon and chem-
ical scaffolds produced from them. Furthermore, the scaffolds of corresponding
sets are compared and the overlap is recorded. In most cases the overlap be-
tween two sets or subsets is very small. Only two carbon scaffolds are shared
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Table 2.3: Carbon scaffold distribution
Selectives Inverse-Selectives
carbon unique carbon unique
Dats sets ligands scaffolds scaffolds ligands scaffolds scaffolds Overlap
5HT1a
and Alpha1 46 16 10 27 14 8 0
D1 and D2 31 15 11 26 7 5 1
D1 and D4 13 5 3 20 4 1 0
5HT1a and D2 24 10 5 11 1 0 0
D2 and D4 9 2 0 64 12 4 1
D3 and D4 12 6 3 33 16 12 0
Cat K and S 25 14 8 20 17 14 0
Thro and FaXa 52 26 21 48 24 18 2
Tryp and FaXa 25 14 10 48 29 17 0
Thro and Tryp 35 30 27 20 10 7 1
HTS Cat B 23 15 12 HTS Cat L or S 0
HTS Cat L 33 28 25 HTS Cat B or S 0
HTS Cat S 23 18 15 HTS Cat B or L 0
Selectives Non-Selectives
carbon unique carbon unique
Dats sets ligands scaffolds scaffolds ligands scaffolds scaffolds Overlap
CA IV/I (6-7) 10 2 1 20 10 6 1
Cat K/B (6-7) 12 9 7 11 10 10 0
Cat S/B (6-7) 12 8 6 11 7 4 0
Tryp/Thro (6-7) 13 8 6 35 16 11 1
CA IV/I (7-8) 20 3 1 33 14 8 2
Cat K/l (7-8) 24 13 10 15 14 13 0
Cat K/S (7-8) 20 9 6 16 15 14 0
Cat S/K (7-8) 24 15 10 22 16 13 1
Cat S/l (7-8) 24 15 11 22 17 13 0
Tryp/Thro (7-8) 25 8 4 10 9 8 1
CA IX/I (8-9) 14 7 4 11 7 4 0
Cat K/l (8-9) 31 18 12 10 9 8 0
Cat K/S (8-9) 25 14 9 21 15 12 0
Cat S/K (8-9) 15 13 11 10 10 10 0
Cat S/l (8-9) 14 11 9 13 12 11 0
MMP 2/1 (8-9) 19 11 8 14 5 3 0
MMP 8/1 (8-9) 12 5 2 16 5 3 0
MMP 9/1 (8-9) 24 13 7 16 5 3 0
Distribution of carbon scaffolds in selectivity sets. The number of overlapping scaffolds for
selective vs. inverse-selective sets and selective and non-selective compounds is reported.
’Unique scaffold’ gives the number of carbon scaffolds that only represent a single compound.
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Table 2.3: Chemical scaffold distribution
Selectives Inverse-Selectives
chemical unique chemical unique
Dats sets ligands scaffolds scaffolds ligands scaffolds scaffolds Overlap
5HT1a
and Alpha1 46 29 24 24 18 14 0
D1 and D2 31 16 12 12 10 7 1
D1 and D4 13 6 3 3 8 5 0
5HT1a and D2 24 18 14 14 3 1 0
D2 and D4 9 2 0 0 21 15 0
D3 and D4 12 11 10 10 21 18 0
Cat K and S 25 22 19 19 19 18 0
Thro and FaXa 52 33 26 26 27 22 0
Tryp and FaXa 25 18 15 15 38 30 0
Thro and Tryp 35 35 35 35 13 10 1
HTS Cat B 23 16 16 HTS Cat L or S 0
HTS Cat L 33 30 29 HTS Cat B or S 0
HTS Cat S 23 18 18 HTS Cat B or L 0
Selectives Non-Selectives
chemical unique chemical unique
Dats sets ligands scaffolds scaffolds ligands scaffolds scaffolds Overlap
CA IV/I (6-7) 10 2 1 20 14 12 1
Cat K/B (6-7) 12 9 7 11 10 10 0
Cat S/B (6-7) 12 8 6 11 7 4 0
Tryp/Thro (6-7) 13 10 8 35 21 15 1
CA IV/I (7-8) 20 3 1 33 15 10 2
Cat K/L (7-8) 24 15 12 15 15 15 0
Cat K/S (7-8) 20 11 8 16 16 16 0
Cat S/K (7-8) 24 16 11 22 19 16 1
Cat S/L (7-8) 24 15 11 22 20 16 0
Tryp/Thro (7-8) 25 11 8 10 10 10 1
CA IX/I (8-9) 14 7 4 11 8 6 0
Cat K/L (8-9) 31 27 24 10 10 10 0
Cat K/S (8-9) 25 21 18 21 20 19 0
Cat S/K (8-9) 15 13 11 10 10 10 0
Cat S/L (8-9) 14 11 9 13 12 11 0
MMP 2/1 (8-9) 19 12 9 14 6 4 0
MMP 8/1 (8-9) 12 9 6 16 6 4 0
MMP 9/1 (8-9) 24 18 14 16 5 3 0
Distribution of chemical scaffolds. The number of overlapping scaffolds for selective vs.
inverse-selective sets and selective and non-selective compounds is reported. ’Unique scaffold’
gives the number of chemical scaffolds that only represent a single compound.
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by two sets in every benchmark system (Thro and FaXa, and CA IV/I 7-8) and
two chemical scaffolds (CA IV/I 7-8). This situation becomes understandable
by comparing the number of ligands, different scaffolds, and unique scaffolds
in each set. ’Unique scaffold’ is the number of scaffolds that only represent a
single compound. The intra-set overlap is comparably low and, on average, the
number of unique scaffolds is slightly smaller than the number of all scaffolds;
therefore, a set contains mostly molecules with different scaffolds and just a
few analogues. A detailed scaffold analysis reveals that independent of the tar-
get (sub)family, identical or very similar carbon skeletons occur in compounds
having large differences in selectivity (Stumpfe et al., 2007). This corresponds
to a scenario where closely related analogues have dramatic differences in selec-
tivity. Otherwise, distinct carbon scaffolds represent compounds at high and
low levels of selectivity. This corresponds to a situation where different series
of compounds are more or less selective. Thus, the selectivity sets combine
chemically distinct series of compounds having different levels of target selec-
tivity with compound series where closely related analogues markedly differ in
selectivity.
These observations suggest that there are no simple structural rules for
selectivity differences within our benchmark systems and that different types of
structure-selectivity relationships are covered (see Section 2.4). These findings
suggest that distinguishing between these sets of compounds having different
selectivity profiles is likely to present a non-trivial problem for compound clas-
sification or other computational similarity methods.
2.4 Structure-Selectivity Relationships (SSRs)
A variety of structure-selectivity relationships (SSRs) is represented in the com-
pound sets. The similarity property principle (SSP) states that structurally sim-
ilar molecules are likely to have similar biological activity (Johnson & Maggiora,
1990). Thus, global molecular similarity is often associated with the biological
response behavior of small molecules. Although the SPP is very intuitive, it is
also inconsistent with general medicinal chemistry experience: a minor struc-
tural modification might lead to a substantial change in compound potency
(Kubinyi, 1998). In the selectivity sets reported here, structural similarity is
correlated with compound selectivity in very different ways. The study of SSRs
adds another level of complexity to structure-activity relationship (SAR) analy-
sis of compounds (Peltason & Bajorath, 2007) because structural modifications
of ligands are likely to lead to different changes in potency against individual
targets, which often leads to complex SSR phenotypes. In the two designed
selectivity test systems, SSRs are partly very different in nature.
In Figure 2.7 shows two representative examples of sets from the first test
system with bidirectional selectivity for different pairs of closely related target
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Figure 2.7: SSRs in selective and inverse-selective compound sets
Different types of structure-selectivity relationships in compound sets are presented. ’SR’
represents the selectivity ratio of the ligand for two targets. As a measure of structural
similarity, ’Tc’ reports pair-wise MACCS Tanimoto coefficient values. Structures are taken
from the ’D2/5HT1a’, ’Thro/Tryp set’, and ’Tryp/Thro’ sets of Stumpfe et al. (2007) .
proteins. On the left side, two molecules from the same set have high structural
similarity (MACCS Tc 0.98), but show significant differences in their selectiv-
ity (SR of 76 versus SR of 1621). In contrast, on the right side, two similar
compounds (MACCS Tc 0.86) belong to two different sets with inverse-directed
selectivity in a significant extent (SR of 2931 for thrombin compared to trypsin
and SR of 173 for trypsin over thrombin).
In the second benchmark system even more complex SSRs are present.
Such relationships are illustrated in Figure 2.8 which shows the variety of SSRs
covered by one exemplary compound series. As one would intuitively expect,
analogues have the same selectivity (bottom left) and diverse structures are
found to exhibit different selectivity (top right). However, also inverse SSRs
occur with high frequency, i. e. closely related structures show significant differ-
ences in their selectivity profile (top left) and diverse structures have the same
selectivity (bottom right). These findings suggest that structurally similar as
well as structurally diverse compounds are selective for the same target and
ligands with distinct selectivity are related to each other by different degrees
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Figure 2.8: SSRs in selective and non-selective compound sets
Different types of structure-selectivity relationships are illustrated that are present in a set
of cathepsin enzyme inhibitors. Structurally similar as well as diverse molecules display
different selectivity patterns. ”SR” means selectivity ratio and is calculated as the quotient
of the potency values of a ligand for cathepsin S over cathepsin K. As a measure of structural
similarity, ”Tc” reports pair-wise MACCS Tanimoto coefficient values. Structures are taken
from the ”cat S/K 7-8 set” (Stumpfe et al., 2008).
of structural similarity. Therefore, the analysis of global molecular similarity
alone is not sufficient to predict selectivity profiles.
2.5 Summary
The two compound systems presented in this chapter contain ligands with dif-
ferent selectivity profiles against different target proteins taken from families
of the biogenic amine G-protein coupled receptors (GPCRs), the chymotrypsin
(S1) family of serine proteases, the matrix metalloprotease family M1, thiol
proteases from the papain (C1) family and carbonic anhydrases (Rawlings et
al., 2008).
In the context of chemical biology, a major challenge for and goal of
computational approaches is to successfully mine databases for molecules that
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can distinguish between different targets within a protein family or subfam-
ily. The compound benchmark systems reported herein are designed to permit
the evaluation or development of computational methods for applications in
chemical biology that depend on the use of target-selective compounds. Great
care was taken to assemble high-quality compound sets with well-defined se-
lectivity patterns. We have analyzed the selectivity sets in detail, and confirm
that they contain diverse chemotypes and compounds, represent different de-
grees of diversity between sets for target pairs, and capture different types of
structure-selectivity relationships. Based on these findings, we can consider
that selectivity differences can not simply be captured by comparison of global
molecular similarity. The availability of selective and non-selective compounds
within each set makes it possible to compare the ability of computational meth-
ods to distinguish between active and target-selective compounds for a target
pair. The use of our two benchmark systems in order to detect target-selective
molecules by so-called selectivity searching will be the focus of the following
chapter.
The represented benchmark systems are freely available through the fol-
lowing link: http://www.lifescienceinformatics.uni-bonn.de/.
Chapter 3
Selectivity Searching
This chapter reports on the use of the two selectivity benchmark systems to
compare virtual screening methods for their ability to discriminate compouds
with different selectivity profiles. The major goal of our analyses has been
to determine whether 2D fingerprint methods have the (perhaps unexpected)
potential to detect and distinguish between compounds having different selec-
tivity against closely related targets. The ability to aid in the identification
of selective molecular probes through compound database mining is of consid-
erable interest for applications in chemical biology. Section 3.2 describes the
performance of different state-of-the-art 2D fingerprint methods by discrimi-
nating selective ligands from inverse-selective ligands (Vogt et al., 2007); and
Section 3.3 investigates preferred search strategies to enrich database selection
sets with target-selective compounds (Stumpfe et al., 2008).
3.1 Similarity and Selectivity Searching
Similarity searching has a long history in pharmaceutical research and contin-
ues to be one of the most widely used ligand-based virtual screening (LBVS)
approaches (Willett, 2006). Reasons for its popularity might in part be due
to computational efficiency and intuitive use, which is well in accord with the
similarity property principle (SPP) (Johnson & Maggiora, 1990). In a typical
similarity search application, computational tools are analyzed to transform
molecules into a binary bit string, termed molecular fingerprint, a special de-
scriptor to characterize a molecule and its properties. Dependent on the fin-
gerprint, bit positions might code for structural keys, atom environments, or
property descriptors, as illustrated in Figure 3.1. The resemblance of database
compounds to one or a few active reference structures is assessed based on
the quantification of fingerprint overlap using a similarity metric. Then the
database molecules are ranked in the order of decreasing similarity, and top-
ranked molecules are thought to have a high potential to share similar biological
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Figure 3.1: 2D Fingerprint
Bit positions are set on (to 1, here marked in grey) if, for example, a structural fragment is
present in a molecule or a chemical property is met (molecular weight (MW) smaller than
500 Da).
activity with reference compounds.
In chemoinformatics, fingerprints are among the most widely used sim-
ilarity search tools (Willett, 2005, 2006) and various designs have been intro-
duced (Eckert & Bajorath, 2007). Fingerprint searching conventionally aims at
the identification of molecules having similar activity to known active reference
molecules. However, fingerprints have not yet been investigated for their abil-
ity to identify target-selective compounds and distinguish between compounds
having similar activity: a search scenario referred to as selectivity searching.
Compound selectivity is thought to be more difficult to study computationally
than activity because selectivity analysis requires the evaluation of compounds
binding to multiple targets.
3.2 Selectivity Searching with Selective and
Inverse-Selective Molecules
In the first selectivity study we investigated the potential of similarity searching
to detect compounds having different selectivity for two targets. We have ana-
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Table 3.1: Selectivity sets of benchmark system 1
Selectivity set Selectives Inverse set Inverse selectives
D1/D2 31 D2/D1 26
D1/D4 13 D4/D1 20
D2/D4 9 D4/D2 64
D3/D4 12 D4/D3 33
D2/5HT1a 11 5HT1a/D2 24
Alpha1/5HT1a 27 5HT1a/Alpha1 46
Cat B/L 23 Cat L/B 33
Cat B/S 23 Cat S/B 23
Cat L/S 33 Cat S/L 23
Cat K/S 25 Cat S/K 20
Thro/Tryp 35 Tryp/Thro 20
Thro/FaXa 52 FaXa/Thro 49
Tryp/FaXa 25 FaXa/Tryp 48
Compounds in each set are selective for one target over another family member. For example,
the designation D1/D2 means that the compounds in this set are selective for dopaminergic
receptor subtype D1 over D2.
lyzed different 2D fingerprint methods for their ability to differentiate between
compounds having different selectivity against closely related targets and dis-
tinguish them from inactive database compounds. The first benchmark system
contains selectivity sets directed against 13 targets in three distinct families,
as summarized in Section 2.2.2, and was used to compare the performance of
five different 2D fingerprint methods at different levels of compound selectiv-
ity: selectivity at the level of (1) target families and (2) on individual target
proteins.
3.2.1 Material and Methods
The compounds of the molecular selectivity benchmark system are divided into
26 selectivity sets containing varying numbers of compounds, as summarized
in Table 3.1. Compounds in each of the selectivity set within our benchmark
system provide an individual test case and pairs of sets (T1/T2, T2/T1) are
available to probe target selectivity relationships, i. e. searching for compounds
selective for target T1 over T2 and vice versa.
For similarity searching, selectivity sets were added to one of two differ-
ent background databases, dependent on the sources of selective compounds.
Ligands of GPCRs and inhibitors of serine proteases were generally taken
from the scientific literature. These compounds were added to a subset of
the ZINC database (Irwin & Shoichet, 2005) consisting of ∼1.44 million com-
pounds having unique 2D structures. All ZINC compounds were considered
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decoys. Compound data for the cathepsins B, L, and S (in part) were taken
from high-throughput screening experiments and, therefore, a different back-
ground database was used for these selectivity sets. This background database
was assembled as the intersection of inactive molecules from each of three high-
throughput screens for inhibitors of cathepsin B, L, and S, respectively. It
consists of 55,055 compounds showing no measurable activity against any of
these targets.
We selected five 2D fingerprints for our analysis that represent different
designs and, in addition, have significantly different complexity. These finger-
prints are MACCS, consisting of 166 bits; TGT, 1704 bits; Molprint2D, no bit
representation (Bender et al., 2004); PDR-FP, 500 bits (Eckert & Bajorath,
2006); and MP-MFP, 171 bits (Xue et al., 2003).
• The MACCS key fingerprint consists of a set of 166 catalogued structural
fragments whose presence or absence in a test molecule is detected.
• TGT is a three-point pharmacophore-type 2D fingerprint that accounts
for triangles of four atomic features using graph distances that are divided
into six distance ranges.
• Molprint2D generates varying numbers of strings that represent layered
atom environments. The number of strings can become very large for
complex molecules (up to 250 strings are theoretically possible).
• PDR-FP (property descriptor value range-derived fingerprint) encodes
value ranges of 93 molecular descriptors and represents a molecular size-
independent fingerprint with constant bit density that can be trained
on different compound activity classes. This fingerprint was especially
designed for similarity searching using multiple reference compounds.
• MP-MFP is a hybrid fingerprint consisting of a combination of structural
keys and binary transformed molecular property descriptors.
Calculations
In order to evaluate different fingerprint designs for their ability to detect selec-
tive compounds, we used multiple reference compounds and applied a nearest
neighbor approach for similarity scoring (Hert et al., 2004). This type of similar-
ity search protocol has been shown to frequently perform best in comparisons
of alternative search strategies (Hert et al., 2004; Willett, 2006). For each
database compound, the n top-scoring reference compounds were considered
nearest neighbors (k-NN) and their similarity values were averaged to obtain
the final similarity score, as schematically shown in Figure 3.2.
For each selectivity set and fingerprint, 25 independent search trials were
carried out with randomly selected sets of reference molecules and the results
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Figure 3.2: Nearest neighbor (k-NN)
In the k nearest neighbor approach, similarities between the database compounds and its k
nearest neighbors (marked in blue) are calculated and averaged.
were averaged. For selectivity sets containing more than 15 compounds (Table
3.1), 10 reference molecules were chosen; in the remaining cases, half of the
compounds in each set were used as the reference molecules and the other com-
pounds were added to the background database as potential hits. For reference
sets of 10 molecules, five nearest neighbors (5-NN) were considered when de-
termining the similarity score for each database compound; for reference sets
of fewer than 10 molecules, three nearest neighbors (3-NN) were chosen. For
MACCS, TGT, Molprint2D and MP-MFP, the conventional Tanimoto coef-
ficient, Tc (Willett, 2005), was calculated as the similarity measure. The Tc
produces values between 0, for minimal similarity, and 1, for maximal similarity
(as discussed in Section 2.3.1). For two molecules A and B that are represented
by vectors XA = (x1A, x2A, . . . , xnA) and XB = (x1B, x2B, . . . , xnB), Tc is de-
fined as follows:
Tc(XA,XB) =
n∑
i=1
xiAxiB
n∑
i=1
(xiA)
2 +
n∑
i=1
(xiB)
2
−
n∑
i=1
xiAxiB
(3.1)
For PDR-FP, its dot product similarity metric was used instead because PDR-
FP calculations involve the comparison of binary descriptor vectors (represent-
ing individual database compounds) and numerical vectors (compound class
search strings) (Eckert & Bajorath, 2006).
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Figure 3.3: Selectivity Analysis
Evaluation of search results at different ’selectivity levels’: (1) recovery of ’target-selective’
molecules, i. e. molecules with the same selectivity as the reference compounds, and (2) re-
covery of ’pair-active’ molecules, comprising selective and inverse-selective compounds, based
on their selectivity at the level of target-families instead of individual targets.
3.2.2 Results
Selectivity Analysis
Pairs of selectivity sets provide the basis for analyzing the potential of simi-
larity searching to detect selective compounds. For each target pair (T1, T2),
a two-step analysis is carried out. First, compounds selective for T1 over T2
(set T1/T2) are taken as reference molecules and searched against a background
database containing the remaining selective T1/T2 compounds and also com-
pounds belonging to set T2/T1 (i. e. compounds selective for T2 over T1). Then
the calculations are repeated using subsets of T1/T2 compounds as reference
molecules after adding the remaining T1/T2 and all T2/T1 compounds to the
database. This procedure makes it possible to evaluate the search results at
different ’selectivity levels’ as illustrated in Figure 3.3: (1) ’target-selective’
molecules must belong to the same selectivity set as the reference molecules
(i. e. compounds selective for the second target are considered false-positives);
(2) ’pair-active’ compounds belong to both selectivity sets (T1/T2, T2/T1).
Thus, for each target pair, pair-active compounds are defined as the sum of
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target-selective molecules and false-positive active compounds. Pair-active com-
pounds are selective at the level of target families, not individual targets. The
identification of target-selective molecules is the ultimate goal of selectivity
searching. However, the ability to detect pair-active compounds also provides
valuable information, because a search calculation should also distinguish com-
pounds that are selective for different members belonging to the same target
family from irrelevant database compounds. Thus, in addition to the identifi-
cation of target-selective molecules, the ratio of target-selective over pair-active
compounds represents another meaningful measure for the evaluation of search
calculations.
Selectivity Search Data
We have carried out systematic search calculations, as outlined above, for all
26 selectivity sets and five fingerprints. In the following, representative results
are discussed in Figures 3.4 and 3.5 that reflect major trends revealed in our
analysis. All remaining results are provided in Appendix C.1. Furthermore,
Table C.1 in Appendix C reports hit and recovery rates for all fingerprints and
selectivity sets and selection sets of the top 100 database compounds. For each
calculation, maximally possible hit rates are also reported in Table C.1, given
the limited number of potential database hits. Theoretically possible hit rates
for target-selective molecules range from only 5% to 59%. These limits are
important to consider when putting the search performance into perspective.
Table 3.2 presents average search results for each fingerprint and the three
target families studied here.
Detection of Selective Compounds
Figure 3.4 monitors the recovery of target-selective versus false positive active
compounds in database selection sets of increasing size and Figure 3.5 reports
average numbers of correctly identified target-selective and false positive active
compounds. Regardless of the targets, a few general trends are clearly evident.
All fingerprints are capable of detecting target-selective compounds and in a
number of cases (e. g. Figure 3.4.A) their performance is very similar. By con-
trast, for other selectivity sets (e. g. Figure 3.4.B and C), in part significant
differences in search performance are observed. In a number of cases, selection
sets of increasing size only enrich target-selective but not false-positive active
compounds (e. g. Figure 3.4.A), which is reflected by the fact that the ratio of
target-selective compounds remains at the 100% level. In other cases, false-
positive active compounds are gradually enriched as selection sets increase in
size (e. g. 3.4.B and C - except for MACCS). Thus, the curves in Figure 3.4
point downwards. However, when there is a notable tendency to enrich false-
positive active compounds in selection sets, target-selective compounds are al-
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Figure 3.4: Retrieval of selective compounds
Reported is the recovery of hits in selection sets of increasing size, ranging from five to 100
database compounds. The leftmost data point corresponds to the smallest selection set size
of five compounds; then set sizes increase in increments of five compounds. The graphical
representations monitor the retrieval of target-selective versus pair-active compounds, as
defined in the text. The total number of recovered pair-active compounds is reported (top
horizontal axis) and also the percentage (bottom). The vertical axis reports the ratio of
target-selective over pair-active compounds.
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ready enriched in small selection sets. This means that selective compounds
produce high similarity scores and if they are correctly detected, they are de-
tected early. These findings suggest that limiting selection set size is likely to
direct search calculations towards exclusive detection of selective compounds.
Thus, if maximizing compound recall is not a primary objective, focusing on
only small numbers of top-scoring database compounds is indicated to be a
preferred search strategy for the identification of target-selective compounds.
Target-Selective versus Pair-Active Compounds
Figure 3.5 compares the ratio of target-selective versus false positive active
compounds for different fingerprints and reveals that in most cases, signifi-
cantly more selective than false-positive active compounds are found, like in
Figure 3.5.A, which is an encouraging result. Furthermore, differences between
fingerprints are only small for the majority of selectivity sets. However, there
are exceptions across all three target families. For example, for the set Cat
K/S (Figure 3.5.B), essentially all fingerprints show a notable tendency to de-
tect false-positive actives. For the D2/D4 set (Figure 3.5.C), fingerprint TGT
displays a significant tendency to detect false-positive actives, in contrast to
MACCS. However, both fingerprints show comparable performance on target-
selective compounds. Thus, fingerprints show differences in the ratio of false
positive active versus target-selective compounds on a case-by-case basis, but
overall differences are surprisingly small and target-selective molecules are much
more frequently detected than false-positive active compounds.
Differences between Target Families
As shown in Chapter 2, selectivity sets for all three target families differ in
their degree of intra-set structural diversity, although the GPCR ligands tend
to be on average more similar to each other than the protease inhibitors. As ex-
pected, cathepsin inhibitors obtained from high-throughput screening data sets
were structurally most diverse (Figure B.1 in Appendix B.1.2). At least two
structural factors are expected to complicate selectivity analysis: (1) if com-
pounds belonging to different selectivity sets have distinct structural similarity
(as is the case for some of the GPCR sets), it might be difficult to distinguish
between them; (2) on the other hand, if selective compounds show significant
intra-set structural diversity (as is the case for some of the cathepsin inhibitors),
it might be difficult to recognize them as being similar. However, the results
demonstrate that selectivity search calculations are not systematically affected
by general differences in intra- and inter-set structural resemblance. For exam-
ple, calculations on a number of GPCR sets and also on the Cat S/B and Cat
B/S sets (Figures in Appendix C.1) exclusively produce selective compounds.
On the other hand, the Tryp/Thro set generally produce more false-positives
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Figure 3.5: Active versus target-selective compounds
Bar graphs report the amounts of false-positive active (light grey) and target-selective (dark
grey) compounds for each fingerprint method as the average number of these compounds in
differently sized selection sets ranging from 50 to 550 compounds. According to the definition
in the text, the sum of false-positive active and target-selective molecules are pair-active com-
pounds; therefore, the height of the bars represents the recovery of all pair-active compounds.
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Table 3.2: Average hit and recovery rates
Biogenic amine Papain-like Chymotrypsin-like
GPCRs proteases proteases
Tasc Paac Tasc Paac Tasc Paac
MACCS
HR [%] 8.2 9.4 4.6 4.8 10.5 11.6
RR [%] 55.6 19.6 35.1 12.4 39.1 16.3
TGT
HR [%] 7.1 7.6 5.1 6.2 11.0 11.6
RR [%] 49.2 17.6 38.6 16.1 40.4 16.7
Molprint 2D
HR [%] 10.6 11.4 6.4 7.0 14.4 15.5
RR [%] 69.4 26.4 46.7 18.3 52.0 22.4
PDR-FP
HR [%] 5.9 6.3 4.5 6.0 12.4 19.2
RR [%] 44.5 15.2 34 15.8 47.5 29.2
MP-MFP
HR [%] 9.1 9.7 5.1 6.0 10.7 11.5
RR [%] 61.2 22.7 38.4 15.6 38.9 15.8
Average hit and recovery rates (HR and RR, respectively) are reported for the three target
families and selection sets of the top 100 database compounds. ’Paac’ stands for ’pair-active’
compounds and ’Tasc’ stands for ’target-selective’ molecules, as defined in the text.
than the Thro/Tryp set. Thus, the results of selectivity searching using finger-
prints do not simply correlate with differences in the structural resemblance of
compounds; compound class-selective features are indicated to play an impor-
tant role.
Fingerprint Search Performance
Table 3.2 summarizes the average search performance of the different finger-
prints for our three target families. For selection sets of 100 database com-
pounds, hit rates for target-selective compounds are generally below 10% for
GPCR ligands and cathepsin inhibitors and above 10% for serine protease in-
hibitors. However, it must be taken into account that theoretically possible hit
rates for target-selective molecules range from only 5% to 59% (see Appendix
C.1 Table C.1), with an average maximum hit rate of approximately 20% over
all selectivity sets. Furthermore, comparable numbers of target-selective com-
pounds are often found in selection sets of much smaller size (Figures 3.4 and
3.5). Also, only small numbers of false-positive active compounds are detected
in most cases. Although the fingerprints are chosen because they represent dif-
ferent design strategies and have in part very different complexity, differences in
their selectivity search performance are not dramatic. The two simplest designs,
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MACCS and MP-MFP, produce significant recovery rates that are comparable
or larger than those obtained with more complex designs. Overall, Molprint2D
gives highest hit rates on target-selective compounds and PDR-FP lowest (see
also Table C.1). These findings contrast the outcome of similarity search cal-
culations on structurally increasingly diverse compound activity classes where
PDR-FP was often found to perform best (Eckert & Bajorath, 2007; Tovar et
al., 2007). Therefore, in this case the results of activity- and selectivity-oriented
similarity searching do not correspond to each other. This means that molecu-
lar similarity relationships are likely to differ within compound activity classes
and selectivity sets and that recognizing compounds having similar activity
against a single target or detecting molecules with different target selectivity
challenges search methods in different ways. Clearly, a characteristic feature of
our search calculations is that target-selective compounds are typically found in
small database selection sets. Another important observation is that in about
half of the test cases, recognition of false-positive actives does not significantly
increase when larger sets of database compounds are selected. Thus, these
calculations have notable specificity.
3.2.3 Discussion
In this first selectivity study, we systematically tested different state-of-the-art
2D fingerprint designs on our molecular selectivity set system and have shown
that they can be successfully used for selectivity searching. We have found that
these fingerprints display an in part surprising ability to detect compounds
that are selective for individual targets within families. These initial findings
are encouraging. Although selectivity search performance has only been
moderate in some of the test cases studied here, an interesting finding has
been that essentially all fingerprints we tested displayed the potential to detect
selective compounds in small database selection sets, regardless of their design
and complexity. This suggests that it might not necessarily be required to
develop conceptually novel computational methods to aid in chemical genetics
and genomics applications. Rather, existing methods might be adapted for
such tasks. To achieve these goals, there will be a growing need for relevant
molecular benchmark systems and test cases, which have been a major limiting
factor thus far in the computational study of compound selectivity. The results
presented herein also suggest that different molecular similarity relationships
determine compound activity and target-selectivity. Our finding that 2D
fingerprints of markedly different complexity frequently yield comparable per-
formance in selectivity-oriented similarity searching should lay the foundation
for further systematic computational studies of molecular selectivity using
these and other methods.
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3.3 Selectivity Searching with Selective and
Non-Selective Molecules
The findings of the previous study reveal that 2D fingerprint methods were able
to distinguish between selective and inverse-selective compounds. Based on our
second benchmark system we have the opportunity to add another level of com-
plexity to selectivity analysis and the simulated virtual screening approach. The
selectivity sets of Benchmark system 2 contain subsets with molecules that are
selective for target T1 over T2 and subsets with molecules showing no significant
selectivity for T1 or T2. Additionally all molecules in a set have a comparable
potency for T1. Therefore, the molecules (two subsets form one selectivity set)
have no significant potency differences, i. e. they are all similarly active for T1,
and only differ in the selectivity and non-selectivity for T1 compared to T2. In
many cases, molecules in these selectivity sets are structurally more similar to
each other than in the first benchmark system and therefore more difficult to
distinguish by computational methods.
For selectivity analysis, we started with comparing the bit frequencies
of the MACCS bit positions for selective and non-selective compounds as a
basis for the ability of fingerprints to discriminate between both subsets. Fur-
thermore we applied fingerprints in combination with nearest neighbor and
centroid methods or na¨ıve Laplacian-corrected Bayes classifiers to search for
target-selective ligands using single- and dual-step compound selection schemes.
The underlying idea was to establish a preferred search strategy to distinguish
target-selective compounds from non-selective and inactive compounds.
3.3.1 Material and Methods
The compounds of the second selectivity benchmark system are divided into 18
selectivity sets containing varying numbers of selective and non-selective com-
pounds, as summarized in Table 3.3. Compounds in each of the selectivity set
within our benchmark system provide an individual test case. For similarity
searching, selectivity sets were added to a subset of the MDDR consisting of
152,337 compounds with unique 2D structures. Inhibitors for the targets com-
prising our selectivity sets and inhibitors against closely related targets were
removed from the MDDR prior to search calculations. We have chosen the
MDDR as a background database because of the lead- or drug-like character of
the majority of its molecules.
For similarity searching, only two fingerprints of the previous study were
selected: MACCS and Molprint2D. These two fingerprints were chosen because
they produced overall best results in our initial selectivity search investigation.
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Table 3.3: Selectivity sets of benchmark system 2
Selectivity set Selectives Non-selectives
CA IV/I 6-7 10 20
CA IV/I 7-8 20 33
CA IX/I 8-9 14 11
MMP 2/1 8-9 19 14
MMP 8/1 8-9 12 16
MMP 9/1 8-9 24 16
Cat K/B 6-7 12 10
Cat S/B 6-7 12 11
Cat K/S 7-8 20 16
Cat K/L 7-8 24 15
Cat S/K 7-8 24 22
Cat S/L 7-8 19 27
Cat K/S 8-9 25 21
Cat K/L 8-9 31 10
Cat S/K 8-9 15 10
Cat S/L 8-9 14 13
Try/Thr 6-7 13 35
Try/Thr 7-8 25 10
Compounds in each set are either selective for one target over another family member or non-
selective for these targets. For example, the designation ’CA IV/I’ means that the selective
subset within this set consists of compounds that are selective for carbonic anhydrase IV over
carbonic anhydrase I, while compounds of the non-selective subset have comparable activity
against both targets.
Calculations
Calculations were carried out using multiple reference compounds with three
different search strategies including nearest neighbor analysis (Hert et al., 2004),
centroid fingerprint searching (Schuffenhauer et al., 2003), and a na¨ıve Bayesian
classification approach (Bender et al., 2004; Mitchell, 1997). For each selectivity
set and fingerprint, 10 independent search trials were carried out with randomly
selected sets of reference molecules and the results were averaged. Half of
the compounds in each selectivity set were used as reference molecules and
the remaining compounds were added to the screening database as potential
hits. For nearest neighbor searching, half of the top 50% (or a minimum of
three) of the reference molecules were used for similarity scoring. For all search
calculations, the conventional Tanimoto coefficient (Tc) (Section 3.2.1) served
as the similarity measure.
Similarity searching was carried out in two different ways: one-step (1S)
and two-step (2S) calculations, as illustrated in Figure 3.6. In 1S calcula-
tions, selective molecules were directly used as references to search for selective
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Figure 3.6: System setup
Summary of selectivity search calculations.
database compounds. In sequential 2S calculations, both selective and non-
selective compounds were first used as references to pre-select the top-ranked
5000 database compounds. Then, in the second step, only selective reference
molecules were used. In the first and second step, either the k-NN strategy,
centroid approach, or Bayesian classification were applied.
For na¨ıve Bayesian classification calculations (1S and the first step of
2S), the training sets consisted of 1000 randomly chosen database molecules
(inactives) and the selective (1S) or selective plus non-selective (2S) (all ac-
tives) reference sets. For the second step of S2, the training sets consisted of
selective reference molecules and non-selective reference molecules.
In a final 2S calculation, the best performances of 1S and 2S calculations
were fused. Thus, the k-NN was applied in the first step with selective refer-
ence molecules to pre-select 5000 database compounds to achieve high recall
of selective molecules. In the second step, Bayesian classification was applied
using training sets of selective versus non-selective molecules (best ratio of se-
lective/active molecules).
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Bit Frequency Analysis
For bit frequency (bf) analysis, the log ratio of relative frequencies of each
individual bit position of the MACCS fingerprint was calculated for (i) the
entire selectivity set versus the background database and (ii) the selective versus
non-selective subsets of each selectivity set:
bf = log(
Aj/NA
Bj/NB
) (3.2)
In this equation, NA and NB represent the total number of compounds in set
A and B, respectively, and Aj and Bj are the number of compounds in set A
and B that have bit position j set on (to 1). If Aj or Bj is zero, a Laplacian
correction is applied and Aj/NA is replaced by 1/(2—NA—) or Bj/NB replaced
by 1/(2—NB—). This correction assumes that a bit position j, which is not set
on in any of the compounds of a data set, is set on once in a data set of twice
the size.
3.3.2 Results
MACCS Bit Frequency Analysis
Based on the MACCS bit frequency setting we attempted to answer the ques-
tion whether selective, non-selective, and database compounds produce different
fingerprint bit settings. The presence of notable differences in bit settings is
a pre-requisite for discriminating between different compound classes in fin-
gerprint search calculations and also for using fingerprints as descriptors for
Bayesian classification. In other words, if different compound classes do not pro-
duce characteristic bit patterns, they can hardly be distinguished by fingerprint
comparison. Therefore, we have determined log ratios of relative frequencies of
bit settings in MACCS:
• for selectivity sets (i. e. all actives) versus database compounds (i. e. inac-
tives) (Figure 3.7, blue bars on left side) and
• for selective versus non-selective compounds (Figure 3.7, red bars on right
side).
We focused only on the MACCS fingerprint because of its consistent format
and moderate size, whereas Molprint2D does not have predefined features and
generates varying numbers of strings.
Representative results are shown in Figure 3.7. A number of MACCS
bit positions had distinctly different frequency in selectivity sets and MDDR
database compounds. Furthermore, we also detected bit positions that were set
on with very different frequencies in selective and non-selective compounds, al-
beit in general only a few. Figure 3.7.A shows 21 bit positions that distinguish
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Figure 3.7: Fingerprint bit frequencies for targets CA IV and IX
The histograms report log ratios of relative bit frequencies for the MACCS fingerprint and
different compound comparisons. Bit positions that differ between selectivity sets of the two
targets and MDDR database compounds are shown on the left (blue bars). Bit positions that
differentiate selective compounds from non-selective inhibitors are shown on the right (red
bars). In A, B, and C, comparisons are reported for CA IV/I 6-7, CA IV/I 7-8, and CA IX/I
8-9, respectively.
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selectivity set CA IV/I 6-7 from MDDR compounds. For this set, seven bit
positions discriminate between selective and non-selective compounds. Figure
3.7.A and B show that the CA IV/I selectivity sets in different potency ranges
(6-7 versus 7-8) produced very similar bit profiles. For set CA IV/I 7-8, only five
bit positions differ significantly between selective and non-selective compounds
(red bars). Figure 3.7.C shows that comparison of selective and non-selective
compounds in the CA IX/I 8-9 set produced a bit profile that differed from
the two related selectivity sets. Wheras the active molecules still displayed a
considerable overlap with the actives from the closely related target CA IV,
comparison of bit positions for selective molecules showed no overlap.
Thus, in summary, limited but systematic differences between bit set-
tings were detected between selectivity sets and the MDDR database and be-
tween selective and non-selective compounds. These findings suggested that
fingerprints should, in principle, be capable of distinguishing between selective,
non-selective, and database compounds, provided appropriate search conditions
could be determined. Therefore, we have carried out systematic search calcu-
lations, as described in the Section 3.3.1.
Search Strategy
We decided to explore different search strategies in order to determine whether
a direct search for selective compounds (1S calculations) would lead to dif-
ferent results than a pre-selection of active (i. e. selective and non-selective)
compounds, followed by a search for selective ones (2S calculations) (see Figure
3.6). We were also interested in comparing the results for fingerprint search-
ing with the na¨ıve Bayesian classification using fingerprint features because we
reasoned that limited differences in bit profiles might be further emphasized
through Bayesian modeling that assigns individual weights to bit positions.
Selectivity Searching
Average results from the best performances of our systematic search calculations
are shown in Figure 3.8. Table 3.4 reports detailed results for three selectivity
sets and illustrates selectivity set-specific differences in search performance that
were generally observed.
Figure 3.8.A shows that 1S search calculations using MACCS and Mol-
print2D yielded significant recall rates using centroid and nearest neighbor
search strategies. For example, for database selection sets of 100 compounds,
MACCS produced on average recall rates of ¿40% and Molprint2D of ¿60% for
selective compounds. Importantly, non-selective compounds were only rarely
detected when selective reference molecules were used, which is also evident in
Table 3.4.
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Figure 3.8: Average results from selectivity search calculations
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Figure 3.8: (continued) Average results from selectivity search calculations
Averages of the best results of each search strategy are reported for MACCS and Molprint2D.
In the diagrams at the top of each figure, compound recovery rates (RR) are monitored for se-
lective reference compounds. The diagrams at the bottom report the ratio of selective/active
compounds for recovered active molecules over increasing selection set size. A, 1S calcula-
tions applying the k-NN (red), centroid (blue), or Bayesian (green) search strategy; B, step
two of 2S calculations after pre-selection of 5000 database compounds with the k-NN (red),
centroid (blue), or Bayesian (green) search strategy; C, comparison of all 1S k-NN (blue) line,
2S k-NN (green), and 2S k-NN/Bayes (red) search calculations.
Fingerprint search calculations preferentially identified selective com-
pounds over closely related non-selective ones. Overall, the k-NN search strat-
egy performed best in our test calculations for both fingerprints. Bayesian clas-
sification did not result in higher recall rates than fingerprint searching. For
MACCS, the Bayes classifier produced results that were very similar to centroid
fingerprint searching, but it essentially failed for Molprint2D and database se-
lection sets of up to 500 compounds. A likely reason for this failure was that
Molprint2D produced many features for database training compounds that were
absent in selective and non-selective reference molecules. During training, such
features are subjected to Laplacian correction, which over-emphasizes inactive
training features. Consequently, test compounds are regarded increasingly sim-
ilar, irrespective of selectivity, which lowers compound recall. A subsequent
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Table 3.4: MACCS: Compound recall in mixed 2S k-NN/Bayes calculations
Selection set 10 20 50 100 500 900 1000
Cat K/B (6-7)
step1
actives 12.7 13.6 16.4 16.4 21.8 26.4 28.2
selectives 23.3 25.0 30.0 30.0 40.0 43.3 46.7
non-selectives 0.0 0.0 0.0 0.0 0.0 6.0 6.0
step2
actives 4.6 5.5 9.1 10.0 20.9 27.3 28.2
selectives 8.3 10.0 16.7 18.3 38.3 46.7 46.7
non-selectives 0.0 0.0 0.0 0.0 0.0 4.0 6.0
Cat S/K (7-8)
step1
actives 6.7 8.8 12.1 13.3 24.2 29.6 42.5
selectives 12.3 16.2 22.3 24.6 41.5 49.2 63.1
non-selectives 0.0 0.0 0.0 0.0 3.6 6.4 18.2
step2
actives 6.7 9.6 12.1 14.6 21.3 22.9 36.3
selectives 12.3 17.7 22.3 26.9 39.2 42.3 60.8
non-selectives 0.0 0.0 0.0 0.0 0.0 0.0 7.3
CA IX/I (8-9)
step1
actives 42.3 44.6 46.9 46.9 57.7 61.5 63.9
selectives 78.6 82.9 87.1 87.1 94.3 97.1 97.1
non-selectives 0.0 0.0 0.0 0.0 15.0 20.0 25.0
step2
actives 12.3 19.2 26.2 36.2 53.9 60.0 63.9
selectives 22.9 35.7 48.6 65.7 90.0 97.1 97.1
non-selectives 0.0 0.0 0.0 1.7 11.7 16.7 25.0
Results are shown for three selectivity sets with different degrees of structural diversity.
Reported are recovery rates (%) for step 1 (k-NN fingerprint searching) and step 2 (Bayesian
classification) for all active (selective and non-selective) compounds and the selective and
non-selective subsets.
Bayesian classification with a modified Laplacian correction performed simi-
larly to the k-NN and centroid approaches (see Appendix C.2 Figure C.3).
We expected that Bayesian classification would be a more promising approach
to distinguish between selective and non-selective compounds having similar
numbers of training features. Figure 3.7.B confirms this expectation. In 2S
calculations, Bayesian classification in step 2 substantially increased the recall
of selective compounds with Molprint2D over 1S. However, k-NN searching
also was the overall preferred approach for 2S calculations, followed by cen-
troid fingerprinting. Although Bayesian classification produced lowest recall in
2S calculations, it consistently displayed the best ratio of selective over active
compounds (Figure 3.8).
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Table 3.4: (continued) Molprint2D: Compound recall in mixed 2S k-NN/Bayes calculations
Selection set 10 20 50 100 500 900 1000
Cat K/B (6-7)
step1
actives 26.4 27.3 34.6 38.2 40.9 47.3 47.3
selectives 48.3 50.0 61.7 65.0 68.3 75.0 75.0
non-selectives 0.0 0.0 2.0 6.0 8.0 14.0 14.0
step2
actives 21.8 27.3 29.1 30.9 40.0 46.4 47.3
selectives 40.0 48.3 51.7 53.3 63.3 73.3 75.0
non-selectives 0.0 2.0 2.0 4.0 12.0 14.0 14.0
Cat S/K (7-8)
step1
actives 22.9 32.5 40.8 42.9 45.8 47.1 52.1
selectives 42.3 60.0 75.4 79.2 83.9 85.4 88.5
non-selectives 0.0 0.0 0.0 0.0 0.9 1.8 9.1
step2
actives 19.6 25.4 31.7 35.0 44.2 47.1 48.3
selectives 36.2 46.9 58.5 64.6 81.5 86.9 88.5
non-selectives 0.0 0.0 0.0 0.0 0.0 0.0 0.9
CA IX/I (8-9)
step1
actives 46.2 46.2 50.8 51.5 60.0 60.0 60.0
selectives 85.7 85.7 88.6 90.0 97.1 97.1 97.1
non-selectives 0.0 0.0 6.7 6.7 16.7 16.7 16.7
step2
actives 39.2 42.3 43.1 43.1 50.8 60.0 60.0
selectives 72.9 78.6 80.0 80.0 88.6 97.1 97.1
non-selectives 0.0 0.0 0.0 0.0 6.7 16.7 16.7
These findings also suggested to explore a 2S search strategy using k-NN
calculations in step 1 in order to maximize the recall of selective compounds in
the pre-selection step, followed by Bayesian classification in step 2 to best dis-
criminate between selective and non-selective compounds. The results of these
calculations are reported in Figure 3.8.C and compared with the two results
of k-NN 1S and 2S calculations. Interestingly, the k-NN/Bayes 2S calculations
produced lower recall than the 1S and 2S k-NN calculations, but an improved
selectivity ratio. However, the selectivity ratio was already high for k-NN cal-
culations, i. e. close to 90% for selection sets of 100 database compounds and
both fingerprints. Thus, the improvement through Bayes classification was only
marginal. The overall lower compound recall of the k-NN/Bayes calculations
was a consequence of lower than average recall of Bayesian classification dur-
ing step 2. Thus, overall k-NN calculations were the preferred search strategy.
Moreover, Figure 3.8.A and B also shows that 2S calculations offered essen-
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tially no advantage over 1S calculations, both in terms of compound recall and
selectivity ratio. Thus, single-step fingerprint calculations using selective refer-
ence compounds and nearest neighbor similarity were found to be an attractive
approach to selectivity searching.
3.3.3 Discussion
The selectivity sets of benchmark system 2 were designed to consist of both se-
lective and non-selective compounds that were organized according to different
potency levels. A key finding of our analysis has been that a simple nearest
neighbor-based fingerprint search strategy is capable of distinguishing between
various structure-selectivity relationships and produces significant recall of se-
lective compounds over non-selective ones. In selectivity searching, MACCS
keys are again found to perform better than it is often observed in conventional
similarity searching for active compounds. Although only a few MACCS bit
positions differ between selective and non-selective compounds, the selectivity
ratio produced by MACCS was high and comparable to the much more complex
Molprint2D fingerprint. These observations suggest future studies to evaluate
other low-complexity fragment-based fingerprints for their ability to distinguish
between selective, non-selective, and random database compounds.
3.4 Summary
The identification of small molecules that are selective for individual targets
within target families is an important task in chemical biology. We aim at the
development of suitable compound sets for computational approaches in order
to study structure-selectivity relationships and predict target-selective ligands.
Our two benchmark systems enabled us to evaluate different computational ap-
proaches to search for target-selective compounds in large databases. The first
selectivity set system presents a sound basis for the introduction of selectivity
searching as it exclusively contains molecules with different selectivity for indi-
vidual targets within protein families. The second benchmark system is further
refined through the inclusion of potency values. In the presented benchmark
studies, we introduce the concept of selectivity searching based on two differ-
ently designed selectivity set systems. The identification of compounds with
target selectivity or differential selectivity patterns typically requires signifi-
cant experimental efforts. Therefore, the interest in computational approaches
to support this process is currently increasing. These results presented here ex-
pand the scope and application radius of similarity-based methods in chemoin-
formatics that are typically used for the identification of molecules active against
a single target. As a practical application, selectivity searching for new cathep-
sin K selective ligands will be the focus of the following chapter.
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Chapter 4
Experimental Application
This chapter introduces in silico selectivity searching with a recently designed
fragment-based fingerprint and a dynamic mapping algorithm for the prediction
of new cathepsin K inhibitors. We report the identification of two non-peptidic
cathepsin K inhibitors that have a clear selective tendency over cathepsin L
and S. These inhibitors were identified by assaying only 16 candidate molecules
taken from ∼3.7 million virtually formatted database compounds (Stumpfe et
al., 2009).
4.1 Selectivity Searching for Cathepsin K
Inhibitors
Finding small molecules that selectively interact with individual target proteins
within target families is a major task in medicinal chemistry and chemical biol-
ogy (Stockwell, 2004). Currently, the identification of suitable small molecules
mostly relies on screening of diverse or specialized compound libraries (Tan,
2005). By contrast, computational methods have thus far only contributed
very little to the identification of molecules that are target-selective or have a
selective tendency (Bajorath, 2008a). In the previous chapters we have adapted
ligand-based computational screening methods for selectivity searching and now
practically apply these methodologies in the search for cathepsin K-selective in-
hibitors. On the basis of computational analysis, 16 candidate molecules taken
from ∼3.7 million database compounds were tested and two inhibitors identified
that showed on average ∼five-fold selectivity for cathepsin K over cathepsin S
and L. Furthermore one of these inhibitors represents a previously unobserved
chemotype.
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CatL    APRSVDWREKGYVTPVKNQGQCGSCWAFSATGALEGQMFRKTGRLISLSEQNLVDCSGPQ  60 
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CatK    --NDGCGGGYMTNAFQYVQKNRGIDSEDAYPYVGQEESCMYNPTGKAAKCRGYREIPEGN 117 
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CatL    -------------------------------------- 
CatS    WLVKNSWGHNFGEEGYIRMARNKGNHCGIASFPSYPEI 217 
 
Figure 4.1: Protein sequence alignment of cathepsins K, L, and S
Equal amino acids occuring more than once on the same position are boxed in grey. Conserved
amino acids in all three enzymes are additionally labled in blue. Sequence information are
drawn from PDB entries 1YK7 (cathepsin K), 1MHW (cathepsin L), and 1MS6 (cathepsin
S) (Berman et al., 2000). Multiple alignment was generated using CLUSTAL W2.
4.1.1 Cathepsins and Their Inhibitors
The cathepsins K, S, and L are cysteine proteases belonging to the papain super-
family of thiol proteases (Bro¨mme & Kaleta, 2002) and are thus closely related
with sequence identities for mature enzymes of 56-60% (cathepsins K and L
60%, S and K 57%, and S and L 56% (a¨gler, a¨gler)), as illustrated in Figure
4.1. In addition to overall high sequence similarity, the active sites have a high
degree of conservation, which represents a difficult task for similarity methods
to identify selective ligands that distinguish between these enzymes. The three
cathepsins are involved in important physiological processes such as antigen
presentation, bone remodeling, or apoptosis (Bro¨mme & Kaleta, 2002; Vasil-
jeva et al., 2007). Accordingly, cathepsins have become relevant drug targets
for the potential treatment of different diseases including cancer, osteoporo-
sis, rheumatoid arthritis and autoimmune disorders (Bro¨mme & Kaleta, 2002;
Vasiljeva et al., 2007; Stoch & Wagner, 2008).
Cathepsin inhibitors are typically substrate analogues with an elec-
trophilic ’warhead’. First generation inhibitors contain a strongly reactive group
that covalently modifies the active site cysteine. More recently, second genera-
tion reversible covalent inhibitors have also been introduced with a less-reactive
functional group, typically a nitrile, which renders these inhibitors reversible
and more desirable for therapeutic applications. However, these compounds
form a covalent reversible bond with the catalytic cysteine residue, as schemat-
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Figure 4.2: Inhibition with a peptidyl nitrile
Typically, inhibitors of cathepsin K utilize an electrophilic ’warhead’, e. g. a nitrile, to interact
with the catalytic cysteine residue by forming a covalent reversible bond. This figure was
adapted from Otto and Schirmeister (1997).
ically shown in Figure 4.2.
Among these cysteine proteases, cathepsin K has attracted particular
interest. It is predominantly expressed in osteoclasts that mediate bone re-
sorption and capable of cleaving native type I collagen, the major component
of bone matrix, and other components of bone matrix such as osteopontin
and osteonectin (Stoch & Wagner, 2008). Because bone matrix degradation
is necessary for osteoclastic bone resorption, cathepsin K constitutes a major
therapeutic target for the treatment of osteoporosis and is also implicated in
rheumatoid arthritis and osteoarthritis (Bro¨mme & Kaleta, 2002; Vasiljeva et
al., 2007). There have been considerable efforts to develop selective cathepsin
K inhibitors because simultaneous inhibition of cathepsins S or L is thought to
be associated with unwanted side effects (Falgueyret et al., 2005; Gauthier et
al., 2008). However, the design proved to be challenging due to the high degree
of structural and mechanistic similarity of the cathepsins. Only recently, the
first inhibitors of human cathepsin K with selectivity over cathepsin S and L,
balicatib (Falgueyret et al., 2005) and odanacatib (Gauthier et al., 2008), have
proceeded to clinical evaluation.
Given their therapeutic potential and the difficulties experienced in the
design of selective cathepsin K inhibitors, we have considered the search for
cathepsin K inhibitors that are selective over both cathepsin S and L, a chal-
lenging and relevant test case for selectivity searching.
4.1.2 Compound Reference Set
The computational screening methods applied here (see Section 4.1.3) extrap-
olate from known ligand information in order to identify structurally diverse
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Figure 4.3: Reference set selectivity
The figure reports the potency and selectivity distribution of the compound reference set used
for selectivity searching. The set consists of literature inhibitors that display at least 50-fold
higher potency for cathepsin K than cathepsin S or L. Compounds were only considered
if potency against all three enzymes was reported in the literature. Each chosen reference
inhibitor is represented by a K/S as well as a K/L symbol. The horizontal axis reports the
potency of each reference compound against cathepsin K and the vertical axis the potency
ratio used as a measure of selectivity.
compounds having desired properties. Thus, the design of compound reference
sets is generally of critical importance for the outcome of the search calculations.
For the assembly of a reference set for selectivity searching, we have applied
differential compound potency against cathepsins as selectivity criterion. Ac-
cordingly, a total of 69 known inhibitors were assembled from the literature
that had at least 50-fold higher potency against cathepsin K than cathepsin S
and L (i. e. a SR of 50 for K/S and for K/L), representing a relatively large
reference set. Hence each compound in the set preferentially binds to cathepsin
K compared to cathepsin S and L. The potency and selectivity distribution
within this reference set is illustrated in Figure 4.3 and its exact composition
and literature sources are reported in Table D.1 in Appendix D. In Figure 4.3,
each molecule is represented by two symbols, one for its selectivity for cathepsin
K over S and another one for its selectivity for K over L.
Typically, the more reference compounds are utilized for search calcula-
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Figure 4.4: Reference set similarity
In the MACCS Tc matrix similarity values are reported for systematic pairwise compound
comparisons. MACCS Tc values are color-coded according to the following scheme: light
green 0 - 0.2, dark green 0.2 - 0.4, grey 0.4 - 0.6, dark red 0.6 - 0.8, light red 0.8 - 1.
tions, the more chemical information is available for hit identification. However,
the number of reference compounds is usually less important than their chemical
nature, e. g. including many active analogues representing the same chemotype
adds only little structure-activity information. Our reference set of 69 molecules
was structurally heterogenous, as illustrated by a MACCS Tc matrix in Figure
4.4, with an average MACCS Tc similarity of 0.55.
4.1.3 Search Strategy
For our analysis, we have implemented a search protocol that involved two con-
ceptually different in silico methods developed in our laboratory, a compound
mapping algorithm termed DynaMAD (Eckert et al., 2006) and a specialized
type of molecular fingerprint consisting of compound class characteristic sub-
structures, ACCS-FP (Batista & Bajorath, 2008). These methods were practi-
cally applied here because they had been benchmarked for selectivity searching
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in computational studies (Vogt et al., 2008).
The term DynaMAD stands for ’Dynamic Mapping to Activity class-
specific Descriptor value ranges’ (Eckert et al., 2006). This ligand-based vir-
tual screening method uses predefined high-scoring descriptors to map database
compounds to reference class value ranges. The number of selected descriptors
is increased in a stepwise manner during iterative compound mapping. The
basic idea of this approach is to map candidate molecules to regions in chem-
ical reference spaces that are predominantly populated by compounds sharing
desired features such as, for example, a specific biological activity. Through
descriptor dimension extension, the resolution of chemical reference spaces in-
creases and irrelevant database compounds are removed from ’activity islands’
in an iterative manner. In our calculations, the descriptor value ranges for
155 1D- and 2D descriptors available in the Molecular Operating Environment
(MOE) were calculated for the 69 reference set molecules. The determined
value ranges were compared with the background database molecules and the
scores calculated. Dimension extension was carried out over all levels. After
the final 20 dimension extension level, only 50 of ∼3.7 million ZINC (Irwin &
Shoichet, 2005) database compounds remained.
For ACCS-FP generation, a fragmentation algorithm is used to purchase
random fragment populations from molecules. From fragment populations of a
specific compound class (for example, an activity class), ACCS can be extracted
by comparing these fragments with random fragment populations derived from
arbitrary database compounds and selecting fragments that exclusively occur
in a pre-specified number of active compounds. These ACCS sets can then be
used as compound class-specific fingerprints for similarity searching (Batista &
Bajorath, 2006, 2007, 2008). Here an ACCS-FP was generated for selectivity
searching on the basis of the cathepsin K reference sets. For similarity search-
ing using multiple reference compounds (i. e. the entire reference set), k nearest
neighbour (k-NN) search strategies were applied (Hert et al., 2004), 1-NN and
3-NN. As similarity metric, the Tanimoto coefficient (Tc) was used (Willett et
al., 1998). In our search for selective cathepsin K inhibitors, both strategies
were applied to generate a database ranking. From each list, the Tc value of
the 50th ranked compound was determined and used as similarity threshold.
Only compounds reaching this value were further considered, resulting in 54
compounds for the 1NN and 66 for the 3NN approach. In order to remove
compound with very similar core structures or analogues from the selection set,
the cyclic carbon scaffolds and the molecular weight of each compound was
calculated. From groups of compounds with identical scaffolds, the molecule
with minimum molecular weight was selected. This selection step removed 26
compounds from each of the two subsets that had three molecules in common,
thus producing a final selection set of 49 unique compounds.
Both DynaMAD and ACCS-FP calculations were carried out in parallel
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Figure 4.5: Selectivity searching
The diagram summarizes the results of selectivity searching, compound selection, acquisition,
and evaluation.
to screen ∼3.7 million compounds with unique 2D structures taken from the
publicly available ZINC database (Irwin & Shoichet, 2005). A summary of the
selectivity search results is provided in Figure 4.5. On the basis of DynaMAD
and ACCS-FP calculations, only 50 and 49 compounds were selected, respec-
tively. No compound was selected by both methodologies. These selection sets
were combined and from pairs of molecules sharing the same core structure
a compound was omitted, leading to the removal of 32 molecules. Of the re-
maining 67 candidate compounds, only 16 could be obtained from commercial
sources. The molecular structures of the 16 compounds are shown in Figure
D.1 in Appendix D.
These 16 compounds were tested for enzyme inhibition in the collab-
orating laboratory in spectrophotometric assays for cathepsin S and L and a
fluorometric assay for cathepsin K. Assays were repeated multiple times with
yielding consistent results. For a detailed description of cathepsin inhibition
assays see Section D.2 in Appendix D.
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Figure 4.6: Cathepsin K inhibitors
Structures of three of 16 tested compounds that inhibited cathepsin K, S, and L at different
levels are shown. Compounds 1 and 2 are selective for cathepsin K over S and L while
compound 3 is comparably active against all three enzymes.
4.1.4 Results
The three compounds that were found to inhibit cathepsin activity are shown in
Figure 4.6. The compounds activity values (IC50) are located in the micromo-
lar range, which is typically observed for structurally diverse hits identified by
virtual screening (Bajorath, 2002; Shoichet, 2004), and two of these molecules,
compounds 1 and 2, displayed a selective tendency for cathepsin K over both
cathepsin S and L. Compound 1 was ∼five- to six-fold selective for cathepsin
K over S and L and compound 2 was about five-fold selective over S and es-
sentially inactive against L. Compound 1 was identified via ACCS-FP search
and compounds 2 and 3 using DynaMAD. Compound 1 had very low struc-
tural similarity to known cathepsin inhibitors. Its maximum MACCS Tc value
to reference set compounds was only 0.53. The corresponding values for com-
pounds 2 and 3 were 0.79 and 0.80, respectively, which also indicate only limited
structural similarity, below the level at which similarity in biological activity is
4.1 Selectivity Searching for Cathepsin K Inhibitors 57
typically expected (Martin et al., 2002). The similarity among the three com-
pounds is also very low. Compounds 1 and 2 have a MACCS Tc of 0.45, as
well as compound 2 and 3. A MACCS Tc of 0.64 between compounds 1 and
3 is the highest value calculated for the three molecules. This illustrates that
the molecular structures are very diverse and that the computational methods
applied here identified structurally diverse active compounds.
Importantly, no pre-existing pharmacophore information was taken into
account in our selectivity search calculations because the methods we applied
evaluate similarity relationships on a whole-molecule basis (Bajorath, 2002).
In particular, no nitrile group constraint was present and compounds with or
without nitrile groups were computationally selected (8 of 16 tested compounds
had a nitrile group, see Figure D.1 in Appendix D). Compound 2 and the active
but not selective compound 3 contain nitrile groups that are a hallmark of re-
versible cathepsin inhibitors, as mentioned above. By contrast, in compound 1,
no nitrile function or any other electrophilic ’warhead’ is present. For competi-
tive inhibition, as suggested by the experiments, the IC50 values of compound 1
obtained for cathepsin K, S, and L correspond to Ki values of 6.1 µM , 87 µM
and 40 µM , respectively. This selective cathepsin K inhibitor is structurally
distinct from known cathepsin inhibitors and thus a subject for further chemical
optimization.
4.1.5 Discussion
In our study, ligand-based computational screening approaches have been suc-
cessfully utilized for the first time to identify compounds having at least a
target-selective tendency. The majority of our 67 computational candidate
compounds could not be acquired, but testing of only 16 of our candidates
confirmed two weakly selective inhibitors. With compound 1, a previously un-
observed chemotype has been identified. The compounds we have identified
expand the current repertoire of cathepsin K inhibitors by adding new chemo-
types with a target-selective tendency that might be useful as starting points for
the development of strongly selective and non-peptidic cathepsin K inhibitors.
The sucessfull application of different virtual screening methods (fin-
gerprint and mapping methods) reveals the high potential of computational
methodologies to detect target-selective ligands. The combination of virtual
screening and biological testing is thought to be a promising approach in the
search for compounds having a desired selectivity profile.
Chapter 5
Discussion and Conclusion
In this thesis, the introduction of selectivity searching in analogy to similarity
searching is presented. The analysis and prediction of target-selective ligands
mainly relies on the availability of sufficient ligand data and the presence of
suitable compound benchmark set systems. This thesis reports for the first time
the design and evolution of selectivity set systems. Such benchmark systems
are required for the evaluation of computational methods like fingerprints or
mapping algorithms for their potential to distinguish target-selective ligands
from non-selective, inverse-selective, and inactive compounds. On the basis of
the two assembled benchmark systems the ability of several state-of-the-art
2D fingerprint as well as mapping methods to preferentially detect selective
compounds were confirmed. In a practical application of selectivity searching
two new cathepsin K inhibitors with a clear selective tendency have been
identified.
Selectivity Benchmark Systems 1 and 2
Comparing the design strategies of the two benchmark systems reveals an im-
portant difference in the treatment of potency values. In the first set system,
we ultimately concentrate on the selectivity of ligands for targets in a pair-
wise manner. It was the first development of such a selectivity system and the
main reason for it was to investigate if state-of-the art methods for similarity
searching are also able to discriminate between different selectivity profiles of
compounds. This system design might incorporate optimized structures and
raw hits into the same set. One can easily imagine that structural differences
between such compounds might be due to potency differences, in addition to
selectivity differences. This might complicate focusing on structural modifica-
tions that exclusively reflect on different selectivity. However, for our initial
investigations this benchmark system contained sufficient information. By con-
trast, the design of the second benchmark system was more complex. In order to
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concentrate on structural differences related to selectivity variations, we assem-
bled molecules that were selective and non-selective for a given target compared
to another closely related one. Additionally, we assigned a potency threshold
to combine molecules with comparable potency for the target into one set.
Thus, the building of selectivity sets consisting of selective, non-selective, and
inverse-selective ligands for two targets within a given potency range should be
generated. Such compound sets present a preferred platform for the study of
selectivity. Currently, the availability of ligand information is still a limiting
factor in this field.
Computational Methods
In our selectivity studies, we were able to show that different 2D fingerprint
methods and a mapping algorithm could successfully be applied for the iden-
tification of selective compounds. The findings that these fingerprints and
the DynaMAD approach display an in part surprising ability to detect com-
pounds that are selective for individual targets within families is encouraging.
Therefore, it might be well worth to go beyond 2D fingerprints and also ex-
plore the potential of different compound classification and machine learning
methodologies for selectivity studies, which might further improve the pre-
dictive value of selectivity analysis. Further selectivity studies using bench-
mark system 2 with special support vector machines (SVMs) have produced
higher recall than the fingerprint approach (Wassermann et al., in press).
For further investigations, we have made our selectivity sets freely available
(http://www.lifescienceinformatics.uni-bonn.de/), because it is hoped that they
might be helpful to benchmark other computational methods for structure-
selectivity analysis.
Practical Virtual Screening
Experimentally confirmed hits from selectivity searching contain two com-
pounds having a clear target-selective tendency for cathepsin K compared to
cathepsin S and L. However, the target-selectivity of these hits is lower than
the selectivity criterion applied to the reference compounds (i. e. SR ≥50).
The activity of hits from virtual screening typically fall to the micromolar
range (Bajorath, 2002; Shoichet, 2004), because a successful virtual screen
extrapolates from known active compounds and identifies hit structures, rather
than optimized compounds. This situation also results in limited selectivity
of compounds because no highly potent molecules are normally identified that
could also be highly selective. Great differences in potency are a prerequisite
for a high SR. Typically, a target-selectivity of a few orders of magnitude
is the result of intense chemical optimization, and will hardly be achieved
during virtual screening. However, a five- to six-fold selectivity reflects obvious
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preference for cathepsin K over cathepsins S or L inhibition.
In summary, this thesis reports the initial design and application
of selectivity searching including a practical proof-of-concept application.
Appendix A
Software and Databases
Software and databases applied in this thesis are collected below, in alphabetic
order.
AID 543 PubChem BioAssay Summary Cathepsin B (HTS data)
Description: HTS bioassay for cathespin B inhibitors carried out at the
PCMD, available through PubChem (accessed 2007/01).
WebSite: http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=453
AID 560 PubChem BioAssay Summary Cathepsin L (HTS data)
Description: HTS bioassay for cathespin L inhibitors carried out at the
PCMD, available through PubChem (accessed 2007/01).
WebSite: http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=460
AID 501 PubChem BioAssay Summary Cathepsin S (HTS data)
Description: HTS bioassay for cathespin S inhibitors carried out at the PCMD,
available through PubChem (accessed 2007/01).
WebSite: http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=501
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BindingDB
Description: BindingDB is a public, web-accessible database of measured
binding affinities, focusing chiefly on the interactions of protein
considered to be drug-targets with small, drug-like molecules.
Reference: (Liu et al., 2007; Chen et al., 2002a, 2002b, 2001)
WebSite: http://www.bindingdb.org/bind/index.jsp
CLUSTAL W2 European Molecular Biology Laboratory - European Bioin-
formatics Institute (EMBL-EBI)
Description: ClustalW2 is a general purpose multiple sequence alignment pro-
gram for DNA or proteins (accessed 2009/03).
WebSite: http://www.ebi.ac.uk/Tools/clustalw2/index.html
DynaMAD Life Science Informatics, University of Bonn (Germany)
Description: DynaMAD is designed to map database compounds to activity-
specific consensus positions in chemical space representations of
step-wise increasing dimensionality.
Reference: (Eckert et al., 2006)
WebSite: http://www.lifescienceinformatics.uni-bonn.de/
MACCS MDL Information Systems Inc.: San Leandro, CA (USA)
Description: MACCS structural keys represent a 2D fingerprint that consists
of 166 bits coding for 166 structural fragments.
Reference: (McGregor & Pallai, 1997)
WebSite: http://www.mdl.com
Matrix2png UBC University of British Columbia, BC (Canada)
Description: Matrix2png is a program for making visualizations of matrix-
based data.
Reference: (Pavlidis & Nobel, 2003)
WebSite: http://www.bioinformatics.ubc.ca/matrix2png/
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MDDR MDL Information Systems Inc.: San Leandro, CA (USA)
Description: MDL Drug Data Report (MDDR) is a database containing about
160,000 biologically active compounds with target and/or thera-
peutic annotations.
WebSite: http://www.mdl.com/products/knowledge/drug data report/
Merops Daylight Chemical Information Systems Inc.: Aliso Viejo,
CA (USA)
Description: The MEROPS database is a resource for information on pepti-
dases and provides links to supplementary pages.
Reference: (Rawlings et al., 2008)
WebSite: http://merops.sanger.ac.uk/
Molprint2D Unilever Centre for Molecular Science Informatics: Cam-
bridge (UK)
Description: Molprint2D is a 2D fingerprint consisting of sets of atom environ-
ments that are derived from the connectivity table of a molecule
and directly represented as strings (no bit representation).
Reference: (Bender et al., 2004)
WebSite: http://www.molprint.com
MOE Chemical Computing Group Inc.: Montreal, QC (Canada)
Description: The Molecular Operating Environment (MOE) provides appli-
cations for the calculation of property descriptors and several
fingerprint formats including TGD, TGT, and GpiDAPH3.
WebSite: http://www.chemcomp.com
MP-MFP Life Science Informatics, University of Bonn (Germany)
Description: MP-MFP is a hybrid fingerprint consisting of a combination
of structural keys and binary transformed molecular property
descriptors.
Reference: (Xue et al., 2003)
WebSite: http://www.lifescienceinformatics.uni-bonn.de/
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PCMD University of Pennsylvania, PA (USA)
Description: The Penn Center for Molecular Discovery (PCMD) is a multi-
disciplinary center that screens small molecules from around the
world in search of new, potentially useful biologically effective
agents.
WebSite: http://www.seas.upenn.edu/ pcmd/
PDR-FP Life Science Informatics, University of Bonn (Germany)
Description: PDR-FP (property descriptor value range-derived fingerprint)
encodes value ranges of 93 molecular descriptors and represents a
molecular size-independent fingerprint with constant bit density.
Reference: (Eckert & Bajorath, 2006)
WebSite: http://www.lifescienceinformatics.uni-bonn.de/
PubChem NCBI National Center for Biotechnology Information, MD
(USA)
Description: PubChem provides information on the biological activities of
small molecules.
WebSite: http://pubchem.ncbi.nlm.nih.gov/
TGT Chemical Computing Group Inc.: Montreal, QC (Canada)
Description: TGT is a 3-point pharmacophore based fingerprint that accounts
for triangles of 4 atomic features usind graph distances calculated
from the 2D molecular graph. Each atom is given a type.
WebSite: http://www.chemcomp.com
ZINC UCSF University of California: San Francisco, CA (USA)
Description: ZINC is a free database of commercially available compounds in
predicted 3D conformational states. The version of ZINC stud-
ied here contained about 2.1 million molecules filtered for lead-
likeness.
Reference: (Irwin & Shoichet, 2005)
WebSite: http://blaster.docking.org/zinc
Appendix B
Selectivity Sets
B.1 Benchmark System 1
B.1.1 Detailed Compound Composition
Table B.1 shows the detailed description of the compound selectivity sets. Each
assembled compounds is described with its original reference (MDDR or Bind-
ingDB databases, scientific literature or patent sources), the name or number of
the molecule in the original reference and the name of the set in our benchmark
system.
Table B.1: Selectivity sets from benchmark system 1 - Thiol proteases
Thiol proteases Compounds Resources
Cat K/S 123689 MDDR
3, 13, 50, 55, 56, 102, 192, 204, 289 US Patent 7173051
5, 16 US Patent 7064123
14, 15 (Marquis et al., 2005)
3 (Palmer et al., 2005)
JNJ 10329670 (Thurmond et al., 2004)
3f (Thurmond et al., 2004)
Cat S/K 12e, 12g (Crane et al., 2006)
24 (Marquis et al., 2001)
14, 18a, 18g, 18h, 18i, 18j, 18k, 18l, (Palmer et al., 2005)
19a,19b, 19f, 19g, 19i, 19k, 39g, 39l,
39p
11c, 11e, 11d (Patterson et al., 2006)
1, 2, 5 (Ramjee et al., 2006)
15 (Robichaud et al., 2003)
13 (Tavares et al., 2004b)
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Table B.1: (continued) Selectivity sets from benchmark system 1 - GPCRs
GPCR data sets Compounds Resources
5HT1a/ Alpha1 10a, 11a, 12a (Balle et al., 2003)
1, 2, 3, 14 (Bolognesi et al., 1998)
1, 2, 21, 22, 31, 33, 34, 35, 36, (Patane et al., 2005)
38, 39, 40
2b, 2c, 3c, 3d, 6c, 6e, 3f, 6f (Betti et al., 2002)
D2/5HT1a 1a, 1b, 2a, 2b, 3a, 3b, 6a, 7d, (Perrone et al., 2001)
8a, 8c, 8d, 8e, 9a, 10a
2, 3, 4, 6, 7, 20, 33, 34, 35 (Perrone et al., 2000)
Alpha1/5HT1a 1a, 1b, 2a, 2b, 3a, 3b, 6a, 7d, (Perrone et al., 2001)
8a, 8c, 8d, 8e
68725, 94305, 122508, 80070, MDDR
88087, 104250
1, 4 trans, 35, 39, 41, 45, 49, (Peglion et al., 2002)
52, 53, 57, 61, 64, 65, 66, 67,
68, 69, 70, 71
2, 7, 20, 33, 34, 35, 19, 9, 8 (Perrone et al., 2000)
5HT1a /D2 9, 10, 11, 25, 26, 27, 28, 30, (Sukalovic et al., 2005)
31, 33, 43
D1/ D2 48891, 53008, 66712 MDDR
9b (Campiani et al., 2004)
1j (Su et al., 2006)
2, R-3, 29, 30, 31, 32, 33, 43, (Zhang et al., 2007b)
44
9, 10, 13, 22, 25, 26, 27, 30, (Sukalovic et al., 2005)
31, 33, 35, 43
D4/D2 5, 6, 7, 8, 9, 21, 14, 15, 16 (Vangveravong et al., 2006)
D2/D1 43254, 45955, 54185, 61591, MDDR
74760, 81267, 67663, 81609,
57214
17h (Su et al., 2006)
4, 11, 12, 13, 14, 15, 17, 18 (Zhang et al., 2007a)
2, 19, 28, 29, 33, LE 300 (Wu et al., 2005)
66 (Zhang et al., 2007a)
33, 34, 35, 36, 37, 48 (Sasikumar et al., 2006)
D4/D1 2, 19, 20, 28, 29, 33 (Wu et al., 2005)
28,33, 34, 35, 36, 37, 48 (Sasikumar et al., 2006)
D1/D4 3a, 3b, 3d, 3e, 3f, 3g, 3h, 7a, 7b, (Enquehard-Gueiffier et al., 2006)
7c, 7d, 7e, 8a, 8b, 8c, 8d, 8e, 10,
11, 12
D2/D4 8a, 8b, 8c, 8d, 8g, 8h, 8i, 8k, 8l (Egle et al., 2004)
NGD-94-1, L-745,870, U-101,387, (Faraci et al., 1998)
NRA-0045
1, 19, 3e, 5a, 5b, 5c, 5d, 5e, 6a, (Moll et al., 2002)
6b, 7a, 7c, 7d, 16a, 16b, 16c, 16d,
20a, 20b, 20c, 20d, 20e
2a, 2c, 2d, 2g, 2h, 2i, 7, 8, 9 (Hodgetts et al., 2001)
3a, 3b, 3d, 3e, 3f, 3g, 3h, 7a, 7b, (Enquehard-Gueiffier et al., 2006)
7c, 7d, 7e, 8a, 8b, 8c, 8d, 8e, 10,
11, 12
D3/D4 83284, 86208, 87381, 87416, 93148, MDDR
87420, 89805, 91140, 107927, 110975,
89801, 69609
3a, 3b, 3d, 3e, 3f, 3g, 3h, 7a, 7b, (Enquehard-Gueiffier et al., 2006)
7c, 7d, 7e, 8a, 8b, 8c, 8d, 8e, 9,
10, 11, 12
D4/D3 29, 30, 34, 35, 36, 38 (Grundt et al., 2005)
3b, 3c, 3d, 3e, 3f (Bettinetti et al., 2002)
93647 MDDR
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Table B.1: (continued) Selectivity sets from benchmark system 1 - Serine proteases
Serine proteases Compounds Resources
FaXa/Thro 41484, 75442, 78989, 83832, 85591, MDDR
87534, 92902, 95336, 95444, 106874,
108412, 117362, 120836, 121703, 129229,
135043, 143321
pac 3, pgd. 1 BindingDB
1, 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, (Boehm et al., 1999)
15, 16, 17, 18, 19, 21, 22, 23, 24, 26,
27, 29, 31, 32, 34, 35, 36, 40, 44, 46,
52
Thro/FaXa 50806, 59362, 62284, 86682, 90679, MDDR
93002, 94345, 99696, 104533, 104536,
106028, 107065, 108724, 108738, 110238,
113159, 114359, 139559, 160769
Abo 38, 3-Abc 45, 3-Abc 47, 3-Abc 49, BindingDB
3-Abc 50, 3-Abc 6, 3-Abc 70, 3-Abc 81,
3-Abc 82, 3-Oba 1, 3-Oba 28, 3-Oba 29,
3-Oba 3, 3-Oba 39, 3-Oba 4, 3-Oba 45,
3-Oba 46, 3-Oba 48, 3-Oba 49, 3-Oba 5,
3-Oba 50, 3-Oba 51, 3-Oba 54, 3-Oba 56,
3-Oba 59, aci 1, Abo 11a, CRA-16935,
RPR132747, RPR208815
FaXa/Tryp 41484, 83832, 92902, 108412 MDDR
APC-10302, CRA-10991, pac 8, pgd. 1, BindingDB
pgd. 2, pgd. 3
4, 6, 9, 10, 11, 13, 15, 17, 24, 26, (Boehm et al., 1999)
34, 37, 42, 55, 61
Tryp/FaXa 99726, 104026, 104533, 104536, 108625, MDDR
108724, 110186, 110406, 110417, 110878,
112963, 113980, 114359, 114465, 115467,
118098, 118248, 122648, 122963, 123471,
126548, 128228, 135424, 139559, 146060,
153788
Abo 11a, Abo 23, Abo 28, Abo 38, BindingDB
Abo 39, Abo 40, Abo 41, DPC 423,
p[4,3-d]p, 39a, p[4,3-d]p 39b,
p[4,3-d]p 40a, RPR130737, RPR131247,
RPR132747, RPR200095, RPR208815,
RPR208944, RPR209685, Sap 20a, Sap 20c,
Sap 4c, Sap 4d
Tryp/Thro 65709, 70406, 75442, 78203, 78277, MDDR
83874, 84953, 85379, 85623, 87825,
90866, 91816, 92902, 93464, 95336,
95444, 98339, 98545, 99824, 101649,
102874, 106149, 106874, 110951, 117362,
120836, 129229, 135043, 141627, 143314,
143321, 157363
2-kbt 33, 2-kbt 49 BindingDB
5 (Boehm et al., 1999)
Thro/Tryp 102912, 104026, 106028, 106474, 108412, MDDR
111726, 139559
2-kbt 23, 2-kbt 78, APC-10302, BindingDB
APC-10655, APC-10762, CRA-10433,
CRA-10818, CRA-10991, CRA-11852,
CRA-16935, CRA-17693, CRA-18306,
CRA-7806
Used abbreviations for compounds from the BindingDB (Liu et al., 2007; Chen et al., 2002a, 2002b, 2001):
aminobenzioxazole, Abo; amidinobenzylindole carboxamide, Abc; oxybenzamide, Oba; amidine-containing
inhibitor, aci; pyrazolo[..]pyrimidinone, pp; Sulfonamidopyrrolidinone, Sap; ketobenzothiazole, kbt; phenyl-
glycine amide compound, pac; phenylglycine deriv., pgd.
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Table B.1: (continued) Selectivity sets from benchmark system 1 - HTS data sets
HTS data sets Compounds Resources
Cat B 286532, 573353, 646525, 646749, 647599, AID 453
648315, 651936, 653316, 653862, 654815, PubChem BioAssay
655490, 658724, 660829, 714967, 971438,
2212050, 3236798, 3240114, 3241895,
3243128, 3243168, 5293426, 5310676
Cat L 645887, 658255, 660532, 665065, 666453, AID 460
743624, 807549, 2110790, 2997975, PubChem BioAssay
3000014, 3240872, 3241028, 3241115,
3241855, 3243146, 3243294, 3244220,
3244559, 3245560, 5307231, 5307551,
5307860, 5308248, 5308990, 5309581,
5309980, 5742468, 6602827, 6602829,
6603229, 6603344, 6603485, 6603605
Cat S 646956, 647878, 658540, 665907, 667409, AID 501
1523398, 2964469, 3235672, 3241982, PubChem BioAssay
3245121, 5307459, 5307606, 5307613,
5307632, 5308205, 5308405, 5308466,
5308662, 5308835, 5308856, 5309031,
5309909, 5453475
B.1.2 MACCS Tc Matrices
Similarity values are reported for systematic pairwise compound comparisons.
MACCS Tc values are color-coded according to the following scheme: light
green 0 - 0.2, dark green 0.2 - 0.4, grey 0.4 - 0.6, dark red 0.6 - 0.8, light red
0.8 - 1. Compound sets with ”bidirectional” selectivity (selective and inverse-
selective) are compared. For example, the D1 versus D2 matrix (Figure B.1 top
left) compares D1 compounds selective over D2 and vice versa. In each matrix,
pairwise comparisons of compound subsets are divided by black bars.
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0                          1
D1                          D2 D1 D4
D2 D4 D3                D4
5HT1a D2 5HT1a                     Alpha1
Figure B.1: MACCS Tc matrices of selectivity sets from benchmark system 1
72 Appendix B. Selectivity Sets
0                          1
Cat B          Cat L           Cat S Cat K Cat S
Trypsin             Thrombin Factor Xa                Thrombin
Factor Xa                    Trypsin
Figure B.1: (continued) MACCS Tc matrices of selectivity sets from benchmark
system 1
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B.2 Benchmark System 2
B.2.1 Detailed Compound Composition
Table B.1 shows the detailed description of the compound selectivity sets. Each
assembled compounds is described with its original reference (MDDR or Bind-
ingDB databases, scientific literature), the name or number of the molecule in
the original reference and the name of the set in our benchmark system.
Table B.2: Selectivity sets from benchmark system 2
Data sets Compounds Resources
CA IV/I 6-7 Selectives
hsd 12, hsd 13, hsd 14, Hsa 48, Hsa 55, BindingDB
Hsa 58, Hsa 65, Hsa 66, Hsa 67
1 (Nishimori et al., 2007)
Non-selectives
asc 16, asc 18, asc 19, asc 20, asc 21, BindingDB
asc 28, asc 32, DCP, hsc 33, hsc 34,
hsc 37, Hyd 16, Hyd 18, Hyd 22, Hyd 28,
Hyd 35, Tsa 8
11, 19, 20 (Nishimori et al., 2007)
CA IV/I 7-8 Selectives
ahs 9, Hyd 47, Hys 49, Hys 50, Hys 53, BindingDB
Hys 54, Hys 56, Hys 57, Hys 59, Hys 60,
Hys 61, Hys 62, Hys 63, Hys 64, Hys 68,
Hys 69, Hys 70, DZA, hyd 4d
7 (Nishimori et al., 2007)
Non-selectives
IND, ahs 9, asc 22, asc 23, asc 24, BindingDB
asc 25, asc 26, asc 27, BRZ, BZA, EZA,
ahs 36, Hyd 10, Hyd 11, Hyd 13, Hyd 15,
Hyd 17, Hyd 19, Hyd 20, Hyd 21, Hyd 23,
Hyd 25, Hyd 26, Hyd 27, Hyd 29, Hyd 32,
Hyd 7, Hyd 9, MZA, pcs14h, TPM
16, 17, 18 (Nishimori et al., 2007)
CA IX/I 8-9 Selectives
dcs 4, Ind 11c, Ind 12f, Ind 12g, BindingDB
sur 4c, sur 4d, sur 4e, ura 3a, ura 3b,
ura 3c, ura 3d, ura 3e, ura 3f, ura 3g,
ura 3h
Non-selectives
gys 8, pcs 14a, pcs 14b, pcs 14e, BindingDB
pcs 14f, pcs 14t, ret H2c, ret H3,
ret H4, ret H5b
MMP 2/1 8-9 Selectives
suh 23c, asu 13, bsu 7b BindingDB
90937, 124033, 137201, MDDR
4a, 4b, 4f (Pikul et al., 2001)
4h, 4m, 4n, 4o, 4q (Barta et al., 2001)
2b, 2d, 2k, 2l, 2m (Yao et al., 2002)
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Data sets Compounds Resources
MMP 2/1 8-9 Non-selectives
Hyd 10, Hyd 11, Hyd 16, Hyd 22, Hyd 28, BindingDB
Hyd 30, Hyd 31, Hyd 32, Hyd 37, Hyd 44
103242, 128898 MDDR
6a, 6c (Pikul et al., 2001)
MMP 8/1 8-9 Selectives
asu 27b, asu 35f, asu 35g, bsu 7b, BindingDB
bsu 7d
99000, 106288 MDDR
4b, 4c, 4d (Pikul et al., 2001)
Non-selectives
Hyd 10, Hyd 11, Hyd 16, Hyd 17, Hyd 22, BindingDB
Hyd 28, Hyd 30, Hyd 31, Hyd 37, Hyd 38,
Hyd 43, Hyd 44
102964 MDDR
4e, 6a, 6b (Pikul et al., 2001)
7, 9 (Freskos et al., 1999)
MMP 9/1 8-9 Selectives
asu 27b, asu 35f, asu 35g, bsu 7c, BindingDB
bsu 7d, bsu 7e, bsu 7f,
suh 23c, suh 26
106288, 137201 MDDR
4b, 4c, 4d (Pikul et al., 2001)
2a, 2b, 2k, 2l (Yao et al., 2002)
4c, 4e, 4f, 4n, 4p, 4r (Levin et al., 2001)
Non-selectives
Hyd 10, Hyd 11, Hyd 16, Hyd 17, Hyd 22, BindingDB
Hyd 23, Hyd 28, Hyd 29, Hyd 31, Hyd 32,
Hyd 37, Hyd 43, Hyd 44,
4e, 6a (Pikul et al., 2001)
4i (Levin et al., 2001)
Cat K/B 6-7 Selectives
11 (McGrath et al., 2003)
6d (Palmer et al., 2006)
17 (Marquis et al., 1998)
12, 13, 14 (Mendonca et al., 2002)
15 (Robichaud et al., 2003)
2, 7, 10, 18a, 18d (Palmer et al., 2005)
Cat K/B 6-7 Non-selectives
123689 MDDR
1, 5, 8 (Falgueyret et al., 2001)
6, 11 , 25 (Gauthier et al., 2007)
16 (Marquis et al., 1998)
14 (Chowdhury et al., 2002)
20 (Rydzewski et al., 2002)
Cat S/B 6-7 Selectives
20 (Greenspan et al., 2001)
3d, 3f (Thurmond et al., 2004)
6 (Zhou et al., 2002)
14, 15 (Mendonca et al., 2002)
11c (Patterson et al., 2006)
1, 2, 7, 10, 19h (Palmer et al., 2005)
Non-selectives
2 (Ramjee et al., 2006)
8 (DesJarlais et al., 1998)
2 (Gauthier et al., 2007)
13h, 13i, 13k, 16a, 16b (Palmer et al., 2006)
20, 22 (Mendonca et al., 2002)
13 (Rydzewski et al., 2002)
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Data sets Compounds Resources
Cat K/S 7-8 Selectives
17d, 17g (Altmann et al., 2007)
13a, 13b, 13c, 13e (Palmer et al., 2006)
15 (Tavares et al., 2004a)
12c, 12g, 12h, 12i, 12j (Crane et al., 2006)
14, 18e, 18f, 18g, 18h, 18i, 18j, 18k (Palmer et al., 2005)
Non-selectives
7, 8, 13 (Marquis et al., 2005)
3b (Barrett et al., 2007)
5, 7 (McGrath et al., 2003)
2 (Gauthier et al., 2007)
16a (Palmer et al., 2006)
6 (Zhou et al., 2002)
1, 5b (Liu et al., 2005)
15 (Mendonca et al., 2002)
4 (Rydzewski et al., 2002)
13, 25 (Tavares et al., 2004b)
1 (Palmer et al., 2005)
Cat K/L 7-8 Selectives
17d, 17g (Altmann et al., 2007)
13a, 13b, 13c, 13g, 16a (Palmer et al., 2006)
15 (Tavares et al., 2004a)
12b, 12c, 12g, 12h, 12i, 12j (Crane et al., 2006)
13 (Tavares et al., 2004b)
1, 14, 18e, 18f, 18g, 18h, 18i, 18j, (Palmer et al., 2005)
18k
Non-selectives
7, 8, 13 (Marquis et al., 2005)
5, 7 (McGrath et al., 2003)
2, 6, 9 (Falgueyret et al., 2001)
6 (Zhou et al., 2002)
15 (Marquis et al., 1998)
1, 5b (Liu et al., 2005)
20 (Mendonca et al., 2002)
4 (Robichaud et al., 2003)
15 (Zhou et al., 2003)
Cat S/K 7-8 Selectives
15 (Marquis et al., 2005)
21 (Chatterjee et al., 2007)
JNJ (Thurmond et al., 2004)
11, 12, 14, 17, 18, 19 (Tully et al., 2006a)
5d, 5g, 5h, 5j, 5k, 5l, 5r, 5t (Liu et al., 2005)
11d, 11e (Patterson et al., 2006)
14, 15, 23, 26, 27 (Tully et al., 2006b)
Non-selectives
3b, 3c, 3g, 3h, 3i, 3m (Barrett et al., 2007)
2 (Marquis et al., 2001)
7 (Marquis et al., 2005)
7 (Ramjee et al., 2006)
5, 6, 7, 9 (McGrath et al., 2003)
15 (Tavares et al., 2004a)
1, 5a, 5b,5f (Liu et al., 2005)
4, 12 (Rydzewski et al., 2002)
16 (Tully et al., 2006a)
17 (Zhou et al., 2003)
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Data sets Compounds Resources
Cat S/L 7-8 Selectives
1 (Marquis et al., 2005)
3g (Barrett et al., 2007)
21 (Chatterjee et al., 2007)
12e (Inagaki et al., 2007)
JNJ (Thurmond et al., 2004)
11, 12, 14, 17, 18, 19 (Tully et al., 2006a)
15 (Tavares et al., 2004a)
34c (Crane et al., 2006)
11d, 11e (Patterson et al., 2006)
19 (Rydzewski et al., 2002)
14, 15, 23 (Tully et al., 2006b)
Non-selectives
120275 MDDR
15 (Marquis et al., 2001)
6, 7 (Marquis et al., 2005)
3b, 3c, 3h, 3i (Barrett et al., 2007)
4, 7 (Ramjee et al., 2006)
5, 6, 7 (McGrath et al., 2003)
21, 39 (Greenspan et al., 2001)
1, 5a, 5b, 5d, 5f, 5i, 5j, 5k, 5l (Liu et al., 2005)
18, 21 (Mendonca et al., 2002)
27 (Tully et al., 2006b)
Cat K/S 8-9 Selectives
1, 2, 5 (Ramjee et al., 2006)
17a, 17h, 17i (Altmann et al., 2007)
13h, 13i, 13j, 13k (Palmer et al., 2006)
12e, 12f, 13b, 18, 24a (Crane et al., 2006)
18l, 18m, 18o, 19h, 19l, 39a, 39c, 39e, (Palmer et al., 2005)
39h, 39k
Non-selectives
2 (Marquis et al., 2001)
3c, 3f, 3g, 3h, 3i, 3j, 3k, 3m (Barrett et al., 2007)
7 (Ramjee et al., 2006)
4, 6, 9 (McGrath et al., 2003)
5 (Gauthier et al., 2007)
12 (Rydzewski et al., 2002)
8, 12, 21, 28, 29 (Tavares et al., 2004b)
17 (Zhou et al., 2003)
Cat K/L 8-9 Selectives
3c, 3f, 3g, 3m (Barrett et al., 2007)
1, 2, S (Ramjee et al., 2006)
17a, 17h, 17i (Altmann et al., 2007)
3 (DesJarlais et al., 1998)
5 (Gauthier et al., 2007)
13j, 13k (Palmer et al., 2006)
12e, 12f, 13b, 18, 24a (Crane et al., 2006)
18l, 18m, 18n, 18o, 19h, 19l, 39a, 39c, (Palmer et al., 2005)
39e, 39h, 39k
21 (Yamashita & Dodds, 2000)
Non-selectives
3h, 3k (Barrett et al., 2007)
7 (Ramjee et al., 2006)
3, 4, 6, 9 (McGrath et al., 2003)
4 (James et al., 2001)
21 (Mendonca et al., 2002)
13 (Yamashita et al., 2006)
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Data sets Compounds Resources
Cat S/K 8-9 Selectives
123689 MDDR
14 (Marquis et al., 2001)
6, 9, 17 (Gauthier et al., 2007)
12d (Inagaki et al., 2007)
10, 13 (Tully et al., 2006a)
8, 11, 15, 19, 20 (Liu et al., 2005)
20 (Rydzewski et al., 2002)
18 (Tully et al., 2006b)
Non-selectives
8, 13 (Marquis et al., 2001)
3k (Marquis et al., 2005)
4 (Barrett et al., 2007)
16d (Liu et al., 2005)
8, 12, 21, 25, 28 (Tully et al., 2006b)
Cat S/L 8-9 Selectives
123689 MDDR
3f (Barrett et al., 2007)
5, 6, 8, 9, 17 (Gauthier et al., 2007)
12d (Inagaki et al., 2007)
10, 13 (Tully et al., 2006a)
15, 19, 20 (Liu et al., 2005)
18 (Tully et al., 2006b)
Non-selectives
20 (Marquis et al., 2001)
8, 13, 14 (Marquis et al., 2005)
3j, 3k (Barrett et al., 2007)
4 (McGrath et al., 2003)
16d, 17c, 17e, 17j (Altmann et al., 2007)
5c, 8 (Liu et al., 2005)
Try/Thr 6-7 Selectives
102912, 104026, 106028, 106474, 107914, MDDR
111726, 139559
CRA-10818, CRA-11260, CRA-11852, BindingDB
CRA-17312, APC-10762, APC-10972
Non-selectives
93002, 110406, 121703 MDDR
10, 13, 18, 19, 21, 24, 25, 26, 32, 33, (Boehm et al., 1999)
34, 35, 38, 39, 42, 48, 49, 50, 51, 54,
55, 57, 78, 80, 81, 82, 83
CRA-20818, CRA-9462, CRA-9678, pac 8, BindingDB
ben 7
Try/Thr 7-8 Selectives
99726, 146287, MDDR
2-ket 23, APC-10302, APC-10655, BindingDB
CRA-10433, CRA-10991, CRA-11111,
CRA-7806, CRA-8696, CRA-9075, DPC 423,
phd 3
7i, 8b, 8c, 8d, 8e, 8f, 8g, 8h, 8i (Zhao et al., 2000)
8b, 8d, 8e (Shaw et al., 2002)
Non-selectives
41484, 76178, 92322, 99696 MDDR
CRA-15441, phd 1 BindingDB
9, 11, 14, 37 (Boehm et al., 1999)
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Used abbreviations for compounds from the BindingDB (Liu et al., 2007; Chen et al., 2002a, 2002b,
2001): Dichlorophenamide, DCP; Hydroxamate, hyd; Hydroxysulfonamide, Hys; aromatic sulfonamide com-
pound, asc; Topiramate Sulfamide Analogue, tsa; heterocyclic sulfonamide compound, hsc; halogenosul-
fanilamide deriv., hsd; Hydroxysulfonamide, hsa; aromatic sulfonamide compound, asc; Topiramate, TPM;
Methazolamide, MZA; Brinzolamide, BRZ; aromatic/heteroaromatic sulfonamide, ahs; Dorzolamide, DZA;
disulfide-containing sulfonamide dcs; glycoconjugate sulfonamide, gys; Indanesulfonamide Derivative, ind;
pyridinium-containing sulfonamide analog, pcs; reduced thio, ret; sulfonyl urea, sur; urea analog, ura; Sultam
Hydroxamate, suh; alpha-sulfone, asu; beta-sulfone, bsu; benzylamine, ben; phenylglycine amide compound,
pac; ketobenzothiazole, ket; phenylglycine deriv., phd.
B.2.2 MACCS Tc Matrices
Similarity values are reported for systematic pairwise compound comparisons.
MACCS Tc values are color-coded according to the following scheme: light
green 0 - 0.2, dark green 0.2 - 0.4, grey 0.4 - 0.6, dark red 0.6 - 0.8, light red
0.8 - 1. For different selectivity sets, selective and non-selective compounds are
compared (in the order selective — non-selectives). In each matrix, pairwise
comparisons of compound subsets are divided by black bars.
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Tryp/Thro 6-7 Tryp/Thro 7-8
Figure B.2: MACCS Tc matrices of selectivity sets from benchmark system 2
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0                          1
CA IV/I 6-7 CA IV/I  7-8   
MMP 8/1 8-9 MMP 9/1 8-9
CA IX/I 8-9 MMP 2/1 8-9
Figure B.2: (continued) MACCS Tc matrices of selectivity sets from benchmark
system 2
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0                          1
Cat K/B 6-7 Cat S/B 6-7   
Cat S/K 7-8 Cat S/L 7-8
Cat K/S 7-8 Cat K/L 7-8
Figure B.2: (continued) MACCS Tc matrices of selectivity sets from benchmark
system 2
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Cat K/S 8-9 Cat K/S 8-9   
Cat S/K 8-9 Cat S/L 8-9
Figure B.2: (continued) MACCS Tc matrices of selectivity sets from benchmark
system 2
Appendix C
Calculations Data
C.1 All Results from Section 3.2
Table C.1 reports for each fingerprint the average hit (HR) and recovery rates
(RR) of pair-active (Paac) and target-selective (Tasc) compounds among the
100 top scoring database compounds. The ”max. HR” column reports the
theoretically possible maximum hit rate for each selectivity set, given that the
number of potential hits in the background database is always smaller than 100.
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Figure C.1: Retrieval of selective compounds
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Figure C.1: (continued) Retrieval of selective compounds
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Figure C.1: (continued) Retrieval of selective compounds
The figure reports the recovery of hits in selection sets of increasing size, ranging from five
to 100 database compounds in increments of five compounds. The graphical representations
monitor the retrieval of target-selective versus pair-active compounds, as defined in the text.
The total number of recovered pair-active compounds is reported (top horizontal axis) and
also the percentage (bottom). The vertical axis reports the ratio of target-selective over
pair-active compounds.
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5HT1a/D2 14                  11
Alpha1/5HT1a  17                  46
5HT1a/Alpha1 36                  27
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Figure C.2: Actives versus target-selective compounds
C.1 All Results from Section 3.2 89
D2/5HT1a 5                   24
D1/D2 21                  26
D2/D1 16                  31
MACCS                  Molprint2D                      TGT      PDR-FP                   MP-MFP
100 350                    100   350                   100   350    100   350                    100   350
Selection set              Selection set              Selection set            Selection set              Selection setA
v
.
 
n
o
.
 
o
f r
ec
o
v
er
ed
 
ac
tiv
es
A
v
.
 
n
o
.
 
o
f r
ec
o
v
er
ed
 
ac
tiv
es
A
v
.
 
n
o
.
 
o
f r
ec
o
v
er
ed
 
ac
tiv
es
A
v
.
 
n
o
.
 
o
f r
ec
o
v
er
ed
 
ac
tiv
es
A
v
.
 
n
o
.
 
o
f r
ec
o
v
er
ed
 
ac
tiv
es
Target-selectives 
MACCS                  Molprint2D                      TGT      PDR-FP                   MP-MFP
100 350                    100   350                   100   350    100   350                    100   350
Selection set              Selection set              Selection set            Selection set              Selection setA
v
.
 
n
o
.
 
o
f r
ec
o
v
er
ed
 
ac
tiv
es
A
v
.
 
n
o
.
 
o
f r
ec
o
v
er
ed
 
ac
tiv
es
A
v
.
 
n
o
.
 
o
f r
ec
o
v
er
ed
 
ac
tiv
es
A
v
.
 
n
o
.
 
o
f r
ec
o
v
er
ed
 
ac
tiv
es
A
v
.
 
n
o
.
 
o
f r
ec
o
v
er
ed
 
ac
tiv
es
MACCS                  Molprint2D                      TGT      PDR-FP                   MP-MFP
100 350                    100   350                   100   350    100   350                    100   350
Selection set              Selection set              Selection set            Selection set              Selection setA
v
.
 
n
o
.
 
o
f r
ec
o
v
er
ed
 
ac
tiv
es
A
v
.
 
n
o
.
 
o
f r
ec
o
v
er
ed
 
ac
tiv
es
A
v
.
 
n
o
.
 
o
f r
ec
o
v
er
ed
 
ac
tiv
es
A
v
.
 
n
o
.
 
o
f r
ec
o
v
er
ed
 
ac
tiv
es
A
v
.
 
n
o
.
 
o
f r
ec
o
v
er
ed
 
ac
tiv
es
8
4
0
25
15
5
0
20
10
0
8
4
0
25
15
5
0
20
10
0
8
4
0
25
15
5
0
20
10
0
8
4
0
25
15
5
0
20
10
0
8
4
0
25
15
5
0
20
10
0
False positives
Figure C.2: (continued) Actives versus target-selective compounds
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D1/D4  7                   20
D4/D1 14                  13
D2/D4  4                   64
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Figure C.2: (continued) Actives versus target-selective compounds
C.1 All Results from Section 3.2 91
D4/D2 54                  9
D3/D4 6                   33
D4/D3 23                  12
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Figure C.2: (continued) Actives versus target-selective compounds
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Cat L/B 23                  23
Cat B/L 13                  33
Cat S/B 13                  23
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Cat B/S 13                   23
Cat L/S 23                  23
Cat S/L 13                  33
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Cat K/S 15                   20
Cat S/K 10                  25
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Tryp/Thro  10                  35
FaXa/Thro 39                  52
Thro/FaXa  42                  49
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Tryp/FaXa 15                  48
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Figure C.2: (continued) Actives versus target-selective compounds
Bar graphs report the amounts of false-positive active (light grey) and target-selective (dark
grey) compounds for each fingerprint method as the average number of these compounds
in differently sized selection sets ranging from 50 to 550 compounds. According to our
definition in the text, the sum of false-positive active and target-selective molecules are pair-
active compounds, therefore the complete height of the bars represents the recovery of all
pair-active compounds.
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Table C.1
Target-selectives Pair-actives
MACCS max. max.
HR[%] HR[%] RR[%] HR[%] HR[%] RR[%]
D1/D2 21.0 12.2 57.9 47.0 14.4 30.7
D2/D1 16.0 7.0 43.5 47.0 7.3 15.6
D1/D4 7.0 2.8 39.4 27.0 2.8 10.2
D4/D1 14.0 9.4 67.1 27.0 9.4 34.8
D2/D4 4.0 3.7 93.0 68.0 3.7 5.4
D4/D2 59.0 12.4 21.1 68.0 12.4 18.3
D3/D4 6.0 4.4 72.7 39.0 4.4 11.4
D4/D3 27.0 9.4 35.0 39.0 9.5 24.3
D2/5HT1a 5.0 4.3 85.6 29.0 4.3 14.8
5HT1a/D2 18.0 9.6 53.3 29.0 9.6 33.1
Alpha1/5HT1a 17.0 11.0 65.0 63.0 11.0 17.5
5HT1a/Alpha1 36.0 12.0 33.4 63.0 12.0 19.1
Cat B/L 13.0 5.2 40.3 46.0 5.2 11.4
Cat L/B 23.0 1.2 5.0 46.0 1.2 2.5
Cat B/S 13.0 5.2 40.3 36.0 5.2 14.6
Cat S/B 13.0 7.3 56.3 36.0 7.3 20.3
Cat L/S 23.0 1.2 5.0 46.0 1.4 3.0
Cat S/L 13.0 7.3 56.3 46.0 7.3 15.9
Cat K/S 15.0 5.2 34.6 35.0 5.8 16.6
Cat S/K 10.0 4.3 42.8 35.0 5.2 15.0
Thro/FaXa 42.0 26.4 63.0 91.0 26.5 29.1
FaXa/Thro 39.0 11.3 29.0 91.0 12.3 13.5
Tryp/FaXa 15.0 9.0 60.0 63.0 12.3 19.5
FaXA/Tryp 38.0 8.1 21.3 63.0 9.6 15.2
Tryp/Thro 10.0 5.0 50.0 45.0 5.6 12.4
Thro/Tryp 25.0 2.9 11.5 45.0 3.4 7.6
Target-selectives Pair-actives
TGT max. max.
HR[%] HR[%] RR[%] HR[%] HR[%] RR[%]
D1/D2 21.0 10.2 48.8 47.0 14.0 29.8
D2/D1 16.0 4.8 30.0 47.0 5.5 11.7
D1/D4 7.0 3.0 42.3 27.0 3.0 11.0
D4/D1 14.0 9.0 64.6 27.0 9.0 33.5
D2/D4 4.0 3.2 80 68.0 5.3 7.8
D4/D2 59.0 10.3 17.5 68.0 10.5 15.4
D3/D4 6.0 3.0 50.6 39.0 3.0 7.8
D4/D3 27.0 9.0 33.6 39.0 9.0 23.3
D2/5HT1a 5.0 4.1 82.4 29.0 4.1 14.2
5HT1a/D2 18.0 9.0 49.8 29.0 9.0 30.9
Alpha1/5HT1a 17.0 8.2 48.5 63.0 8.2 13.1
5HT1a/Alpha1 36.0 14.6 40.6 63.0 14.6 23.2
Cat B/L 13.0 6.4 49.6 46.0 6.4 14.0
Cat L/B 23.0 1.2 5.2 46.0 1.2 2.6
Cat B/S 13.0 6.4 49.5 36.0 6.4 17.9
Cat S/B 13.0 6.3 48.6 36.0 6.3 17.6
Cat L/S 23.0 1.2 5.2 46.0 2.3 5.0
Cat S/L 13.0 6.3 48.6 46.0 6.3 13.7
Cat K/S 15.0 7.8 51.7 35.0 12.9 36.8
Cat S/K 10.0 5.0 50.0 35.0 7.3 21
Thro/FaXa 42.0 23.8 56.8 91.0 23.8 26.2
FaXa/Thro 39.0 10.0 25.6 91.0 10.2 11.2
Tryp/FaXa 15.0 10.2 68 63.0 11.4 18.1
FaXA/Tryp 38.0 13.9 36.5 63.0 14.1 22.3
Tryp/Thro 10.0 4.0 39.6 45.0 5.6 12.5
Thro/Tryp 25.0 4.0 15.8 45.0 4.4 9.8
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Table C.1: (continued)
Target-selectives Pair-actives
Molprint2D max. max.
HR[%] HR[%] RR[%] HR[%] HR[%] RR[%]
D1/D2 21.0 16.7 79.4 47.0 17.7 37.7
D2/D1 16.0 12.3 77.0 47.0 13 27.7
D1/D4 7.0 5.4 77.7 27.0 6.3 23.4
D4/D1 14.0 11.1 79.4 27.0 11.1 41.2
D2/D4 4.0 3.4 86.0 68.0 5.4 8.0
D4/D2 59.0 15.1 25.6 68.0 15.2 22.4
D3/D4 6.0 6.0 99.3 39.0 6.0 15.3
D4/D3 27.0 12.3 45.5 39.0 12.3 31.5
D2/5HT1a 5.0 4.3 86.4 29.0 5.3 18.3
5HT1a/D2 18.0 9.7 54.0 29.0 10.6 36.4
Alpha1/5HT1a 17.0 11.9 69.9 63.0 14.4 22.9
5HT1a/Alpha1 36.0 19.0 52.8 63.0 19.8 31.5
Cat B/L 13.0 6.2 47.4 46.0 6.4 14.0
Cat L/B 23.0 2.8 12.3 46.0 2.8 6.2
Cat B/S 13.0 6.2 47.4 36.0 6.2 17.1
Cat S/B 13.0 7.4 56.6 36.0 7.4 20.4
Cat L/S 23.0 2.8 12.3 46.0 3.0 6.4
Cat S/L 13.0 7.4 56.6 46.0 7.4 16.0
Cat K/S 15.0 12.3 81.9 35.0 15.7 44.9
Cat S/K 10.0 5.9 58.8 35.0 7.5 21.4
Thro/FaXa 42.0 27.3 65.0 91.0 27.3 30.0
FaXa/Thro 39.0 18.0 46.1 91.0 18.4 20.2
Tryp/FaXa 15.0 10.0 66.9 63.0 11.0 17.5
FaXA/Tryp 38.0 18.4 48.4 63.0 22.5 35.7
Tryp/Thro 10.0 5.9 59.2 45.0 6.4 14.2
Thro/Tryp 25.0 6.6 26.2 45.0 7.6 16.8
Target-selectives Pair-actives
PDR-FP max. max.
HR[%] HR[%] RR[%] HR[%] HR[%] RR[%]
D1/D2 21.0 5 23.6 47.0 7.6 16.3
D2/D1 16.0 3.2 20.3 47.0 4.5 9.6
D1/D4 7.0 2.7 38.9 27.0 2.7 10.1
D4/D1 14.0 7.7 54.9 27.0 7.7 28.4
D2/D4 4.0 2.8 70.0 68.0 3.4 5.0
D4/D2 59.0 8.1 13.8 68.0 8.2 12.0
D3/D4 6.0 5.2 86.6 39.0 5.2 13.3
D4/D3 27.0 5.3 19.7 39.0 5.3 13.6
D2/5HT1a 5.0 3.9 78.4 29.0 3.9 13.5
5HT1a/D2 18.0 9.9 54.9 29.0 9.9 34.1
Alpha1/5HT1a 17.0 8.4 49.4 63.0 8.4 13.3
5HT1a/Alpha1 36.0 8.6 23.9 63.0 8.6 13.7
Cat B/L 13.0 4.6 35.4 46.0 4.6 10.0
Cat L/B 23.0 1.6 7.0 46.0 1.6 3.5
Cat B/S 13.0 4.6 35.4 36.0 4.6 12.8
Cat S/B 13.0 5.6 42.8 36.0 5.6 15.4
Cat L/S 23.0 1.6 7.0 46.0 2.3 5.0
Cat S/L 13.0 5.6 42.8 46.0 5.8 12.5
Cat K/S 15.0 7.5 49.9 35.0 11.6 33.0
Cat S/K 10.0 5.2 51.6 35.0 11.9 34.0
Thro/FaXa 42.0 23.2 55.2 91.0 26.3 28.9
FaXa/Thro 39.0 13.0 33.2 91.0 21.7 23.9
Tryp/FaXa 15.0 12.9 86.1 63.0 19.9 31.6
FaXa/Tryp 38.0 9.2 24.1 63.0 21.4 33.9
Tryp/Thro 10.0 3.7 37.2 45.0 10.5 23.4
Thro/Tryp 25.0 12.2 49.0 45.0 15.2 33.7
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Table C.1: (continued)
Target-selectives Pair-actives
MP-MFP max. max.
HR[%] HR[%] RR[%] HR[%] HR[%] RR[%]
D1/D2 21.0 13.4 63.8 47.0 17.9 38.1
D2/D1 16.0 6.5 40.8 47.0 8.6 18.2
D1/D4 7. 0 3.8 54.9 27.0 3.8 14.2
D4/D1 14.0 10.9 77.7 27.0 10.9 40.3
D2/D4 4.0 3.8 96.0 68.0 4.3 6.3
D4/D2 59.0 14.3 24.3 68.0 14.3 21.1
D3/D4 6.0 5.3 88.7 39.0 5.3 13.6
D4/D3 27.0 10.2 37.9 39.0 10.2 26.3
D2/5HT1a 5.0 4.2 83.2 29.0 4.2 14.3
5HT1a/D2 18.0 11.0 61.1 29.0 11.0 37.9
Alpha1/5HT1a 17.0 11.0 64.5 63.0 11.0 17.4
5HT1a/Alpha1 36.0 15.0 42.0 63.0 15.1 24.0
Cat B/L 13.0 5.4 41.2 46.0 5.4 11.7
Cat L/B 23.0 1.4 6.3 46.0 1.4 3.1
Cat B/S 13.0 5.4 41.2 36.0 5.4 14.9
Cat S/B 13.0 7.3 56.3 36.0 7.3 20.3
Cat L/S 23.0 1.4 6.3 46.0 1.5 3.2
Cat S/L 13.0 7.3 56.3 46.0 7.3 15.9
Cat K/S 15.0 7.7 51.2 35.0 10.0 28.6
Cat S/K 10.0 4.8 48.0 35.0 9.5 27.1
Thro/FaXa 42.0 26.0 62.0 91.0 26.1 28.7
FaXa/Thro 39.0 13.8 35.3 91.0 14.8 16.2
Tryp/FaXa 15.0 8.8 58.4 63.0 9.8 15.6
FaXA/Tryp 38.0 8.1 21.4 63.0 9.6 15.3
Tryp/Thro 10.0 4.5 45.2 45.0 5.0 11.02
Thro/Tryp 25.0 2.8 11.0 45.0 3.7 8.2
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Figure C.3: Average results from selectivity search calculations
Averages of the best search calculations of each search strategy are reported for MACCS and
Molprint2D. In the diagrams on the top of each figure, compound recovery rates (RR) are
monitored for selective reference compounds. The diagrams on the bottom report the ratio of
selective/non-selective compounds for recovered active molecules over increasing selection set
size. A, 1S calculations applying the k-NN (red), centroid (blue), or Bayesian (green) search
strategy; B, step two of 2S calculations after pre-selection of 5000 database compounds with
the k-NN (red), centroid (blue), or Bayesian (green) search strategy; C, comparison of all 1S
k-NN (blue) line, 2S k-NN (green), and 2S k-NN/Bayes (red) search calculations.
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Figure C.3: (continued) Average results from selectivity search calculations
Appendix D
Selectivity Searching for
Cathepsin K-Selective Ligands
D.1 Cathepsin K Reference Set
Table D.1 shows the detailed description of the used reference compound set.
Each of the 69 assembled compounds is described with its original reference
from the scientific literature and the number of the molecule used in its original
reference.
Table D.1: Selectivity reference set for cathepsin K
Compounds Resources
24 (Marquis et al., 2001)
4b, 4e, 4g (Altmann et al., 2002)
1, 2 (Ramjee et al., 2006)
17a, 17d, 17g, 17h, 17i (Altmann et al., 2007)
12c, 12e, 12f, 12g, 12h, 12i, 12j, 13b, 18, 19, 24a, 34c, rac 34a (Crane et al., 2006)
13 (Tavares et al., 2004b)
13, 14, 18a, 18e, 18f, 18g, 18h, 18i, 18j, 18k, 18l, 18m, 18n, (Palmer et al., 2005)
18o, 19a, 19b, 19c, 19d, 19e, 19f, 19g, 19h, 19i, 19k, 19l, 19m,
39b, 39c, 39d, 39e, 39f, 39g, 39h, 39i, 39j, 39k, 39l, 39m, 39n,
39o, 39p, 39q, 9
23 (Yamashita & Dodds, 2000)
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D.2 Enzyme Inhibition Assays
Cathepsin K Inhibition Assay
A fluorometric assay (Perkin Elmer luminescence spectrometer LS 55) was used
to measure the activity of recombinant human cathepsin K (expressed in Pichia
pastoris) at 22 ◦C (o¨ser, o¨ser). The wavelengths for excitation and emission
were 360 nm and 490 nm, respectively. Assay buffer was 100 mM sodium cit-
rate buffer, pH 5.0, 100 mM NaCl, 1 mM EDTA, 0.01% CHAPS. An enzyme
stock solution of 1.8 µmol/lM in assay buffer was diluted 1:100 with assay
buffer containing 5 mM DTT and incubated for 30 min at 37 ◦C. Inhibitor
stock solutions were prepared in DMSO. A 20 mM stock solution of the chro-
mogenic substrate Z-Leu-Arg-NH-Mec (Bachem, Bubendorf, Switzerland) was
prepared with DMSO. The final concentration of DMSO was 5% and the fi-
nal concentration of the substrate Z-Leu-Arg-NH-Mec was 40 µmol/lM. Assays
were performed with a final concentration of 0.18 nM of cathepsin K. Into a
cuvette containing 940 µmol/lL assay buffer, inhibitor solution and DMSO in
a total volume of 48 µmol/lL, and 2 µmol/lL of the substrate solution were
added and thoroughly mixed. The reaction was initiated by adding 10 µmol/lL
of the cathepsin K solution and was followed over 8 min. IC50 values were cal-
culated from the linear steady-state turnover of the substrate. A Km value of
5.8 ± 0.4 µmol/lM was obtained in duplicate measurements with eight differ-
ent substrate concentrations. Inhibitory activity, expressed as IC50 value, was
determined from the linear steady-state turnover of the substrate in triplicate
measurements at a single inhibitor concentration.
Cathepsin S Inhibition Assay
Recombinant human cathepsin S (Calbiochem, Darmstadt, Germany) was as-
sayed spectrophotometrically (Cary 100 Bio, Varian) at 405 nm at 37 ◦C. Assay
buffer was 50 mM sodium phosphate buffer, pH 6.5, 50 mM NaCl, 2 mM EDTA,
0.01% Triton X-100. An enzyme stock solution of 866 µmol/lg/mL in 35 mM
potassium phosphate, 35 mM sodium acetate, 2 mM DTT, 2 mM EDTA, 50%
ethylene glycol, pH 6.5. This enzyme solution was diluted 1:100 with assay
buffer containing 5 mM DTT and incubated for 30 min at 37 ◦C. Inhibitor
stock solutions were prepared in DMSO. A 10 mM stock solution of the chro-
mogenic substrate Z-Phe-Val-Arg-pNA (Bachem, Bubendorf, Switzerland) was
prepared with DMSO. The final concentration of DMSO was 5% and the final
concentration of the substrate Z-Phe-Val-Arg-pNA was 100 µmol/lM. Assays
were performed with a final concentration of 86.6 ng/mL of cathepsin S, which
corresponded to an initial rate of 0.6 µmol/lM/min. Into a cuvette containing
940 µmol/lL assay buffer, inhibitor solution and DMSO in a total volume of 40
µmol/lL, and 10 µmol/lL of the substrate solution were added and thoroughly
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mixed. The reaction was initiated by adding 10 µmol/lL of the cathepsin S
solution and was followed over 18 min. IC50 values were calculated from the
linear steady-state turnover of the substrate. A Km value of 75 ± 7 µmol/lM
was obtained in duplicate measurements with nine different substrate concen-
trations. Inhibitory activity, expressed as IC50 value, was determined from the
linear steady-state turnover of the substrate in triplicate measurements at a
single inhibitor concentration.
Cathepsin L Inhibition Assay
Recombinant human cathepsin L (Calbiochem, Darmstadt, Germany) was as-
sayed spectrophotometrically (Cary 100 Bio, Varian) at 405 nm at 37 ◦C (Eilfeld
et al., 2008). Assay buffer was 100 mM sodium phosphate buffer, pH 6.0,
100 mM NaCl, 5 mM EDTA, 0.01% Brij 35. An enzyme stock solution of 50
µmol/lg/mL in 20 mM sodium acetate buffer, pH 5.0, 100 mM NaCl, 10 mM
trehalose, 1 mM EDTA, 50% glycerol was diluted 1:100 with assay buffer con-
taining 5 mMDTT and incubated for 30 min at 37 ◦C. This enzyme solution was
diluted 1:5 with assay buffer containing 5 mM DTT. Inhibitor stock solutions
were prepared in DMSO. A 10 mM stock solution of the chromogenic substrate
Z-Phe-Arg-pNA (Bachem, Bubendorf, Switzerland) was prepared with DMSO.
The final concentration of DMSO was 5% and the final concentration of the
substrate Z-Phe-Arg-pNA was 100 µmol/lM. Assays were performed with a fi-
nal concentration of 4 ng/mL of cathepsin L, which corresponded to an initial
rate of 0.9 µmol/lM/min. Into a cuvette containing 910 µmol/lL assay buffer,
inhibitor solution and DMSO in a total volume of 40 µmol/lL, and 10 µmol/lL
of the substrate solution were added and thoroughly mixed. The reaction was
initiated by adding 40 µmol/lL of the cathepsin L solution and was followed
over 10 min. IC50 values were calculated from the linear steady-state turnover
of the substrate. A Km value of 16 ± 1 µmol/lM was obtained in duplicate
measurements with nine different substrate concentrations. Inhibitory activity,
expressed as IC50 value, was determined from the linear steady-state turnover
of the substrate in triplicate measurements at a single inhibitor concentration.
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D.3 Candidate Molecules
S
O
O
N
H
O
O
N
H
 
 
ZINC01119129 
 
O
O
N
O
O
N
H
N
 
ZINC06539072 
 
OHN
N
 
ZINC02073050 (compound 1) 
 
O
N
O
H
N
O
O
H
N
 
ZINC06600071 
 
O
H
N
N
N
N
N
 
ZINC02317810 (compound 3) 
 
O
N
H
O
O
H
N
O
 
ZINC06758197 
 
Figure D.1: The 16 tested candidate molecules
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Figure D.1: (continued) The 16 tested candidate molecules
Molecular structures of the tested 16 compounds. The ZINC-IDs of the three cathepsin K
inhibitors are printed in bold.
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D.4 Sources of Compounds
Table D.2: Suppliers for candidate molecules
ZINC ID Supplier Order No.
ZINC06600071 Asinex ASN 03883456
ZINC02073050 Asinex BAS 01516888
ZINC04212408 AMRICG X 0745552
ZINC07976221 Enamine-REAL T5510382
ZINC01119129 Vitas-M STK 112067
ZINC05352644 Inter BioScreen STOCK5S 96650
ZINC06758197 Inter BioScreen STOCK6S-13840
ZINC04859896 Inter BioScreen STOCK2S-54064
ZINC02317810 Inter BioScreen STOCK2S-23132
ZINC04497549 Life Chemicals F2539-1063
ZINC07963142 Enamine-REAL Z117028918
ZINC06988985 Enamine-REAL Z102640542
ZINC06539072 Enamine-REAL Z24048596
ZINC07107301 Enamine-REAL Z92650609
ZINC06538926* Enamine-REAL T6083643
ZINC07133910* Enamine-REAL T6083642
*structural analogue, the ZINC number does not match
Active compounds 1, 2, and 3 (see Chapter 4) were purchased from
Asinex (BAS01516888), Enamine-REAL (T5510382), and Inter Bioscreen (2S-
23132), respectively.
Table D.3: Unavailable candidate molecules
ZINC00746972 ZINC03928332 ZINC04653191 ZINC04940202 ZINC00093585
ZINC03817098 ZINC03976177 ZINC03991195 ZINC07432183 ZINC07721236
ZINC00750286 ZINC03933263 ZINC06306807 ZINC06222104 ZINC00601831
ZINC03821224 ZINC04034772 ZINC04371608 ZINC07432263 ZINC07987574
ZINC00750384 ZINC03933268 ZINC06326739 ZINC06733232 ZINC01670127
ZINC03917590 ZINC04188199 ZINC04653211 ZINC07747321 ZINC08028892
ZINC00846242 ZINC03948481 ZINC06569660 ZINC06733233 ZINC03791566
ZINC03917918 ZINC04489969 ZINC04720784 ZINC07947430
ZINC03870497 ZINC03960061 ZINC06717298 ZINC06733234
ZINC03928323 ZINC04547921 ZINC04756514 ZINC08161881
ZINC03966603 ZINC03964070 ZINC07107304 ZINC06744828
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